

BRITISH SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY AND DIABETES

England & Wales · Charity number 1135319

Details

Other names BSPED

Status Registered

Legal form Charitable company

Company number [07003983](#)

Registered 2010-03-30

Register [View on the Charity Commission register](#)

Contact

Address Starling House
Unit 1600
Bradley Stoke
Bristol
BS34 8YU

Phone 01454 642258

Email bsped@endocrinology.org

Website www.bsped.org.uk

Activities

Objects: TO ADVANCE FOR THE PUBLIC BENEFIT EDUCATION IN PAEDIATRIC ENDOCRINOLOGY, DIABETES AND RELATED SUBJECTS BY PROMOTING RESEARCH IN SUCH AREAS AND DISSEMINATING THE USEFUL RESULTS OF SUCH RESEARCH AMONGST HEALTH PROFESSIONAL, SERVICE PROVIDERS AND THE PUBLIC BY THE MEANS OF MEETINGS, PUBLICATIONS IN ANY FORM AND BY ANY OTHER APPROPRIATE MEANS

Activities: The BSPED promotes research and training by encouraging collaboration and open dialogue. The BSPED holds an Annual Conference which incorporates a Training Day and specialist nurses sessions. The committees of the BSPED work to create guidelines, audits and research to advance knowledge and good practice in our specialist area. Information is communicated with members through a monthly newsletter.

Classification

- **How:** Makes Grants To Individuals, Makes Grants To Organisations, Provides Services, Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives
- **Who:** Other Charities Or Voluntary Bodies, Other Defined Groups, The General Public/mankind

Geography

- **Area of benefit:** UNDEFINED. IN PRACTICE, NATIONAL.
- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-08-31	£379,048	£364,450	-	-
2024-08-31	£393,526	£342,078	-	-
2023-08-31	£192,492	£147,528	-	-
2022-08-31	£193,692	£112,598	-	-
2021-08-31	£116,316	£78,877	-	-
2020-08-31	£208,032	£236,870	-	-

Trustees

Name	Role	Appointed
Dr FIONA REGAN		2023-11-09
Dr Senthilkumar KaruppananSenniappan		2024-10-09
Dr Talat Mushtaq		2024-10-09

Accounts

Charity number: 1135319
Company number: 07003983

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Trustees' annual report and financial statements
for the year ended 31 August 2025

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Contents

	Page
Legal and administrative information	1
Trustees' annual report	2 - 12
Independent examiners' report	13
Statement of financial activities	14
Balance sheet	15 - 16
Notes to the financial statements	17 - 22

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Legal and administrative information

Charity registration number 1135319

Company registration number 07003983

Business address c/o Fiona Regan
6 Sherbourne Walk
Farnham Common
SL2 3TZ

Registered office 69 Carter Lane
London
EC4V 5HF

Trustees Dr Fiona Regan, Treasurer
Dr Tabitha Randell (resigned 9 October 2024)
Dr Melanie Kershaw (resigned 9 October 2024)
Dr Talat Mushtaq, Chairman (appointed 9 October 2024)
Dr Senthilkumar Karuppanansenniappan, (appointed 9 October 2024)
Secretary

Accountants Leftley Rowe & Company
Second Floor
87 - 88 Turnmill Street
London
EC1M 5QU

Bankers Lloyds Bank Plc
Kings Heath
32 - 34 Alcester Road South
Kings Heath
Birmingham
B14 7PU

British Society For Paediatric Endocrinology and Diabetes (A company limited by guarantee)

Report of the trustees' (incorporating the directors' report) for the year ended 31 August 2025

The trustees present their report and the financial statements of the charity for the year ended 31 August 2025. The trustees have adopted the provisions of the Statement of Recommended Practice (SORP) 'Accounting and Reporting by Charities' (FRS 102) in preparing the annual report and financial statements of the charity. The directors of the charitable company are its trustees for the purposes of charity law. The directors who served during the year and up to the date of this report are set out on page 1.

Structure, governance and management

The British Society For Paediatric Endocrinology and Diabetes is constituted by a Deed of Trust and is a registered charity No 1135319. The charity changed its status to a company limited by guarantee from 01 September 2010.

Objectives and activities

The aims of the charity are to advance education in paediatric endocrinology and related subjects by promoting research and disseminating the useful results of such research.

In keeping with the aims, the Society shall have the following powers:

1. To arrange and provide for the holding of meetings, lectures and seminars.
2. To procure to be written and print, publish, issue and circulate gratuitously or otherwise such papers, periodicals, pamphlets or other documents.
3. To raise funds and to invite and receive contributions from any person or persons whatsoever by way of subscriptions and otherwise provided that the Society shall not undertake any permanent trading activities in raising funds for its primary charitable objectives.
4. To cooperate, associate or affiliate with any other charitable institutions.
5. To do all such other lawful things as are necessary for the attainment of the above objectives.

The charity has 474 members, who include doctors, scientists, allied professionals (specialist nurses, pharmacists and dietitians) and medical students. During 2024-2025, the Society has been active in presenting clinical and basic research in the field of paediatric endocrinology and diabetes, both to its own members and the wider paediatric community.

Members of the society are represented on committees with other related societies to ensure close liaison, and paediatric endocrinology representation in the drawing up of guidelines. Examples include NICE, European Endocrine Reference Network (Endo ERN), European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA), Diabetes UK, CYP Diabetes Board, Society for Endocrinology and ACDC.

The charity works closely with national agencies for paediatrics and is affiliated with the Royal College of Paediatrics and Child Health, British Endocrine Society, Royal College of Physicians and the Society for Endocrinology. The society also works closely with Patient Support Groups, such as The Child Growth Foundation, The Turner Society Support Group, British Thyroid Foundation, Pituitary Foundation and Living with CAH.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2025

Major areas of activity in support of these objectives

In 2025 we held our annual meeting in Sheffield. It was well attended and delivered an excellent scientific programme with a wide range of topics covering the depth and breadth of paediatric endocrinology and diabetes delivered by renowned speakers, including many local delegates from the adult and paediatric endocrine community. The BSPED 2025 Awards Session was held on the second day of the meeting in which the Plenary talk by the James M Tanner Award winner was delivered by Dr Jeremy Allgrove, detailing his journey throughout his career. Dr Allgrove's work in the arena of calcium and bone endocrinology has significantly contributed to paediatric endocrinology and he has a syndrome bearing his name due to his novel work for that syndrome.

Other highlights included

- o Expert talks/symposia (x 6) delivered by expert speakers
- o Parallel endocrinology and diabetes sessions
- o Personal Practice session and 4 Satellite Symposia
- o Presentations from previous year's BSPED Award winners
- o BSPED 2025 Awards Session
- o Top scoring abstracts as oral communications
- o Guided poster tours
- o CME day including interesting case presentations
- o Nurse and Endocrine Professionals Session
- o How do I? sessions (endocrine & diabetes)

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2025

Key activity 2024-2025

Virtual Paediatric Endocrine Group (VPEG)

- " Managed by Renuka Dias as POC Chair and supported by Dinesh Giri as CME Officer
- " Popular quarterly case presentation sessions with up to 70 people registering for the meetings in 2024

Awards and grants

Overseen by the Awards Committee: Charlotte Elder (Chair), Executive Committee members and Clinical Committee Chair

Current Grants and awards

- " Research & Innovation Award
- " Paediatric Endocrine & Diabetes Nurse & AHP Awards
- " James M Tanner Award (Nominations for 2026 have been entered and a winner selected by a judging panel)
- " Conference Travel Grants

Peer Review

- " BSPED now running a virtual peer review process with a number of reviews taking place in 2025 including Kings College Hospital in London and Alder Hey in Liverpool.

Support for LSBU masters course for nurses

- " BSPED funded 10 Nurses in 2024 to complete this nurse endocrine masters module

NHSE Out-patient Recovery and Transformation Programme

- " BSPED chair represented RCPCH on programme

RCPCH - BSPED been working closely with them on other projects

Paediatric Endocrine Nurse Competency framework - BSPED funded a face-to-face meeting to get an agreed national competency framework for paediatric endocrine nurses

New special interest group set up to look at Pre-diabetes and possible treatments to delay onset of Type 1 diabetes

Growth Study Day - a face-to-face meeting focusing on growth was funded and run by the growth special interest group

Grant and Project funding for 2026 and beyond

- " BSPED now actively seeking ideas and suggestions from its members for projects to fund in coming years.
- " The key criteria for any project is that it would bring benefit to BSPED and the wider Endocrine Community

Membership Fees in 2025

- " BSPED fees increased in 2024 so left at £126 per year for 2025

Royal College of Paediatrics and Child Health Annual Professional Meeting 2025

- o 24th May - Face to face BSPED special interest group symposium
- o Combined session with British Paediatric and Adolescent Bone Group
- o 4 guest speakers and 5 oral communications
- o 41 abstracts submitted: 4 oral presentations at the symposium, 35 as ePosters

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2025

Summary of Clinical Committee Activity 2024-25

Key Activities

Guideline, standards and position statements
Streamline process for review of clinical guideline & standards
Updated: hormone supplementation for pubertal induction in girls (July 2025); use of GnRH analogue shared care (September 2025),

Non-SIG outputs

NHSE laboratory handling of insulin requests in the handling of investigation of hypoglycaemia
UK achondroplasia management guideline (submitted for publication)
UK endo bone monitoring of vamorolone for DMD including management of adrenal suppression during switching from classic CS (published on www.dmdcareuk.org)
UK bone management of adults with DMD including transition (being written for publication; launch online clinician webinar (Thursday 22nd January 4-5 pm)

Surveys

Turner Syndrome UK service evaluation survey (clinician and patient)
Survey on access to technology for CYP with diabetes known to social care.

NICE consultations

Consultation on the use of Teplizumab and draft guidance
Overweight and obesity quality standards
Vasorotide use for achondroplasia

Patient information update

Evorel patch use
DI/AVP deficiency
Pros and cons of GH (Growth SIG)
CAIS (DSD SIG)

Others

NHSE CYP gender service specification
Neonatal and paediatric pharmacy group (NPPG) steroid card and position statement
NICE AI guideline

Paediatric Adrenal Insufficiency steroid card translation

Arabic, Greek, Polish, Romanian, Slovak, Turkish, Urdu, Mandarin

BSPED Paediatric Endocrine Nurse Specialist Competency Developmental Framework
(Peter Laing, Karen Thompson)

Ongoing

BSPED working group on standards of education of paediatric adrenal insufficiency

Ongoing (informed by nurse survey, survey & focus group of parents and CYP via delphi consensus)

Funding from Addison's Disease Self Help Group, Living with CAH and Pituitary Foundation to co-develop (involving care-givers and CYP) national information sheet

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2025

Focus for the coming year (2025-26)

Guidance on development of BSPED patient information leaflets

BSPED AI steroid card translation

Educational standards of paediatric AI

Educational videos on sick day management of AI

Steroid card (NPPG liaise with adrenal SIG)

Consider NICE AI guideline (input from adrenal SIG)

Update guidelines including sex steroid priming guideline

Special Interest Groups

Special Interest Groups

Growth Disorders	Helen Storr	2020-2028
Thyroid	Catherine Peters/Tim Cheetham	2020- 2028
DSD	Zainaba Mohamed	2016- 2025
CAH /adrenal	Nils Krone (Rathi Prasad)	2021-2028
HPAT	Paul Dimitri/Hoong Wei	2019- 2025
T2DM	Pooja Sachdev/Evelien Gevers	2019-2027
Pre-T1DM	Tabitha Randell/Rachel Besser	2025-2029
Research	Indi Banarjee	2025-2029

1. Growth Disorders

Main outputs (2024-25)

Electronic growth chart project: national audit (100+ centres) and inter-software accuracy testing progressed with RCPCH collaboration

Developing national guidance on adjunct growth therapies (GnRHa, aromatase inhibitors).

Developing national guidance on Tall Stature management.

Delivered national education day - "Focus on Growth: Growth Disorders in Childhood" (London, 4 July 2025) with BSPED/industry support

Updated BSPED clinical resources: PIS on pros/cons of hGH; shared-care guidance for hGH; guidance for LAGH use/monitoring.

Engagement & liaison: NICE (LAGH, hGH for Noonan), BNFC (somatotropin sections), NHSE Genomic Laboratory Hubs (gene panels), Generations Study CI.

Strengthened trainee involvement and secured BSPED Exec support for publications from projects (trainees as first authors).

Focus for the coming year (2025-26)

Complete submit manuscripts: (1) Electronic growth chart audit/performance (target: Archives of Disease in Childhood, with RCPCH); (2) Adjunct therapies review (target: European Journal of Endocrinology); (3) Tall Stature guidance to BSPED Clinical Committee.

Plan two further national education days; initial theme: "Growth assessment for primary care" (2026) with BSPED grant support.

Develop new workstreams: Growth monitoring position statement; national IGF I assay audit & SDS calculator; contribute to GlobE Reg rare growth disorder projects.

Hold a dedicated session at the National Meeting to set 2026 research/education priorities and refine SIG strategy.

Deepen collaborations with RCPCH (representation on committees/working groups) and continue liaison with NICE/BNFC/NHSE Genomics.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2025

2. Thyroid

Main outputs (2024-2025)

Initial service evaluation across 4 tertiary centres with research ethics in place; final manuscript in preparation.
Optimised outcome data processes for primary CHT with the Newborn Screening Laboratory.
National questionnaires to newborn labs and BSPED regional committees on CHT data collection; findings presented at the national newborn lab scientific meeting.
Agreed change to the CHT algorithm as requested by Newborn Screening Laboratories.
Collaboration with Generation R team to evaluate thyroid gene panels.
Expert input to British Thyroid Foundation patient information resources.
Shared research themes with the BSPED Research SIG.

Focus for the upcoming year (2025-2026)

Work with BSPED regional networks to improve primary CHT outcome data collection.
Advocate with national newborn screening bodies for a unified UK database for outcome data.
Complete and submit the central CHT manuscript. Assess feasibility and pros/cons of screening for secondary (central) CHT in the UK.
Support, publicise and facilitate recruitment to the NIHR funded Graves' RCT (lead: Wood).

3. DSD

Main outputs (2024-25)

Re-audit of BSPED DSD Standards completed; manuscript in preparation; publication funding secured via BSPED (2025).
Education & professional development relaunched: quarterly case-based discussion meetings.
New research updates shared regularly
Quality Improvement: DSD animation video (BCH) completed and published
Updated BSPED CAIS patient information leaflet.
Engagement & advocacy: promoted SDM projects; contributed to national discussions on sports participation and legal/ethical developments (e.g., April 2025 Supreme Court ruling).
Community & events: active participation around I DSD Symposium activities (Stockholm 2024).

Focus for the coming year (2025-26)

Prioritise Quality Improvement projects to inform updated DSD standards and future publications.
Develop & share referral and transition pathways from larger centres to support national alignment.
Expand patient education resources (additional videos and updated leaflets) with charity partners (DSD Families).
Co-develop an interim position statement on sports participation in young people with DSD with Genomics colleagues; issue joint statement.
Establish a service evaluation exercise/tool via a focus group and pilot across centres.
Continue horizon scanning and facilitated debate on legal/ethical implications (e.g., sport, April 2025 ruling, boxing & DSD roundtable follow up).
Plan for international collaboration and representation ahead of the 12th I DSD Symposium (Lübeck, 1-3 July 2026).

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2025

4. Adrenal/CAH

Main outputs (2024-25)

Advanced collection & analysis of real world data on CAH care across the UK & Ireland.
Oral and poster presentations delivered at BSPED and ESPE meetings.
Initiated planning for a face to face SIG day meeting with industry engagement.
Discussed NICE guidance on adrenal insufficiency.
Launched project strands on rare adrenal insufficiency and adrenal tumours.

Focus for the coming year (2025-26)

Continue long term real world CAH data programme; develop benchmarking across centres.
Deliver investigator initiated trial (substantial funding secured; PI: N. Krone, University of Sheffield).
Produce guidance for rare adrenal conditions (incl. rare AI and adrenal tumours).
Progress plans for a national face to face meeting to share data, standards and research priorities.
Leadership transition to Dr Rath Prasad and refresh membership engagement.

5. HPAT

Main outputs (2024-25)

Regular national & international HPAT case discussions (complex HPAT tumours).
Active roles in SIOP Brain Tumour groups (Craniopharyngioma, Low Grade Glioma) and Sfe ECOL project (endocrine conditions over the lifecourse).
Publications advancing the field: HyOb reviews; MEK/BRAF inhibitor endocrine toxicities; OPG/IGF 1 abnormalities (multi centre collaborations).
Industry-clinical collaboration with Rhythm Pharmaceuticals to support access to setmelanotide for hypothalamic obesity (HyOb).
Clinical trials: TRANSCEND (setmelanotide) phase III RCT completed with excellent primary outcome (?20% BMI reduction overall; ?20.2% in children); Bivamelagon phase II oral MC4R agonist in OLE phase with analyses underway.
Education: contributions to SIOPe BTG education day and BPNA trainees' education; ongoing monthly knowledge sharing MDT.

Focus for the coming year (2025-26)

Sustain monthly national/international HPAT MDT meetings.
Generate further publications on identification and management of HPA tumours.
Establish and mobilise an Optic Pathway Glioma / IGF 1 registry; resolve logistics at AGM.
Work with Rhythm Pharmaceuticals to secure UK access/approval for setmelanotide in HyOb.
Ensure UK centres are ready and participating in forthcoming HyOb trials (e.g., GLP 1 / dextroamphetamine).
Run the 2nd National HPAT Conference and disseminate best practice.
Publish HPAT service outcomes and support ECOL lifecourse endocrine workstreams.
Progress participation in international registries (craniopharyngioma; HyOb studies with NL/Zurich/Denmark).

6. Type 2 Diabetes

Main outputs (2024-25)

Delivered 2 national online study days (Dec 2024; Jul 2025).
Established regional HCP peer-support networks with regular updates to the national group.
Published/updated tools: First Year of Care Pathway; Individual Healthcare Plan for schools.
Developed patient information leaflets on medications with DigiBete; promoted elfh T2D modules.
Supported YoungType2 DigiBete resources and input to NPDA Spotlight T2 work.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2025

Focus for the coming year (2025-26)

Continue twice-yearly national study days and strengthen regional peer networks.
Publish revised ACDC guidance and medication leaflets/resources for families/HCPs.
Pilot a face-to-face training session on T2 service good practice and spread learning.
Run national survey on CGM use and admission at diagnosis; review NPDA Spotlight extended analysis when available.
Sustain First Year of Care implementation and update resources based on feedback.

7. Pre-T1DM

Main outputs (2024-25)

SIG expanded to include wider MDT and transition/adult diabetes representation across the UK.
UK Pre T1D pathway finalised; accepted for publication in Diabetic Medicine (July 2025, open access).
UK HCP survey on managing Pre T1D completed; published in Diabetic Medicine (May 2025).
Audit standards agreed to monitor compliance with and outcomes from the BSPED Pre T1D pathway.
Joint initiative with Sanofi to create regional Pre T1D clinical champions (0.25 PA/week for 12 months) across all UK networks; interviews held Sept 2025.
Initiated collaboration discussions with Sanofi & ABCD on feasibility of screening first degree relatives of CYP with T1D for autoantibodies.

Focus for the coming year (2025-26)

Produce educational videos for HCPs on Pre T1D management and screening.
Develop family facing resources with DigiBete.
Establish and support regional clinical champions; coordinate pathway audit activities.
Collect national audit data on CYP with Pre T1D per the BSPED pathway.
Promote and collaborate with the UK Islet Autoantibody Registry.
Contribute to discussions on emerging disease modifying therapies to delay/prevent T1D.
Contribute to discussions on wider population screening and to any proposed NICE guidance on T1D screening and treatments.
Ensure the Pre T1D pathway is easily accessible on the BSPED website.

8. Research

Main outputs (2024-2025)

3 meetings held and group established (transition from NIHR Clinical Studies Group).
Aims/objectives defined; leadership structure identified.
Member survey launched to manage expectations (analysis pending).
Supported collaboration incl. NIHR-funded multicentre rituximab trial.
Supported national grant applications from BSPED centres.
Trainee development activities initiated.

Focus for the coming year (2025-2026)

Discuss operation as an independent Research Committee with BSPED Exec support.
Enable collaborative, multi-centre grant applications.
Provide peer review for applications and study designs.
Develop infrastructure to support resident doctors in paediatric endocrinology research.
Evolve vision/aims with new coordinator/chair and deputies.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2025

- o Streamlining development of BSPED standards and guidelines
- o Guidance on development of BSPED patient information leaflets
- o BSPED AI steroid card translations
- o Educational standards of paediatric AI
- o Google Analytics to review website engagement
- o BSPED LinkedIn presence
- o Contributions to key NICE consultations: Teplizumab; review of AI guidance, etc
- o Re-launch of GH Audit
- o Honing peer review process
- o Reviewing SIGs and terms of reference

Audits

Work on modernising the growth hormone audit continued in 2024 with the help of a grant from Merck Serono with a plan to restart in 2025.

BSPED Website Development

The website is aimed at:

- " Providing up-to-date useful & relevant information to encourage usage of the site by health professionals as well as patients/carers
- " Facilitating communication & collaboration among BSPED members
- " Promoting our specialty and society nationally and internationally
- " Providing a user friendly e.g. smart phone friendly version

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2025

Other supported activities

The Society supported a number of other activities in 2024-2025 which included:

- " Funded Masters nursing courses in Paediatric Endocrinology, London Southbank University (£12,850)
- " Travel and attendance grants for junior members presenting their research work at annual conferences to the sum of £3,716
- " Educational prizes / research awards £28,800
- " Grant given to host a nation growth study day £10,000
- " Endocrine nurse competency framework development work

Sponsors

There is dedicated financial support to the Society from sponsors from the pharmaceutical industry. In 2025 the partnership, sponsorship and engagement opportunities were expanded to include a variety of different symposia and workstations. Items throughout the year available for purchase include member webinar/email/newsletter advertising/section of the partner resource library. Annual meetings opportunities include satellite symposium/exhibitor/lanyard logo/delegate bag logo. The majority of the sponsored funding is to support the Annual Meeting, growth hormone audit, research grant and educational training sessions for doctors and nurses. Some of the funding is used for Clinical Committee, Executive Committee and Clinical Special Interest Group activities. Funding also contributes to the running of the Society and Secretariat fees.

Financial review

It is the policy of the Society to maintain unrestricted funds, which are the free reserves of the charity. The reserves are held at a level that ensures the future financial viability of the Society. That level is deemed to be one that equates to a minimum of approximately three years' expenditure. Note 14 of the financial statements indicates that there are £1,077,993 unrestricted funds as at 31 August 2025. This provides sufficient funds to cover management, administration and support costs.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2025

Statement of trustees' responsibilities

The trustees are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Generally Accepted Accounting Practice.

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and which enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Small company provisions

This report has been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

This report was approved by the Board on 29 June 2026 and signed on its behalf by



Dr Fiona Regan
Treasurer

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Independent examiner's report to the trustees on the unaudited financial statements of British Society For Paediatric Endocrinology and Diabetes.

I report to the charity trustees on my examination of the financial statements of British Society For Paediatric Endocrinology and Diabetes for the year ended 31 August 2025 set out on pages 12 to 22.

Responsibilities and basis of report

As the charity trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the financial statements of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your company's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.


Independent examiner's statement

Since the company's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in accordance with section 386 of the Companies Act 2006; or
2. the financial statements do not accord with such records; or
3. the financial statements do not comply with relevant accounting requirements under section 396 of the Companies Act 2006 other than any requirement that the financial statements give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Christopher Andrews ACA
Independent examiner

Leftley Rowe & Company
Chartered Accountants and Statutory Auditors
Second Floor
87 - 88 Turnmill Street
London
EC1M 5QU

29 June 2026

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Statement of financial activities (incorporating the income and expenditure account)

For the year ended 31 August 2025

	Notes	Unrestricted funds £	2025 Total £	2024 Total £
Income				
Incoming resources from generating funds:				
Activities for generating funds	2	362,306	362,306	372,064
Income from investments	3	16,742	16,742	21,462
Total income		<u>379,048</u>	<u>379,048</u>	<u>393,526</u>
Expenditure				
Costs of generating funds:				
Cost of generating funds	4	81,692	81,692	65,947
Expenditure on charitable activities	5	276,917	276,917	269,236
Other	7	5,841	5,841	6,895
Total expenditure		<u>364,450</u>	<u>364,450</u>	<u>342,078</u>
Net movement in funds		14,598	14,598	51,448
Reconciliation of funds				
Total funds brought forward		1,063,395	1,063,395	1,011,947
Total funds carried forward		<u>1,077,993</u>	<u>1,077,993</u>	<u>1,063,395</u>

The statement of financial activities includes all gains and losses in the year and therefore a separate statement of total recognised gains and losses has not been prepared.

All of the above amounts relate to continuing activities.

The notes on pages 17 to 22 form an integral part of these financial statements.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Balance sheet
as at 31 August 2025

	Notes	£	2025 £	£	2024 £
Current assets					
Debtors	11	32,636		37,081	
Cash at bank and in hand		1,068,652		1,058,880	
		1,101,288		1,095,961	
Creditors: amounts falling due within one year	12	(23,295)		(32,566)	
Net current assets			1,077,993		1,063,395
Net assets			1,077,993		1,063,395
Charity Funds					
Unrestricted funds	14		1,077,993		1,063,395
Total funds			1,077,993		1,063,395

The Balance Sheet continues on the following page.

The notes on pages 17 to 22 form an integral part of these financial statements.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Balance sheet (continued)

Trustees statements required by the Companies Act 2006
for the year ended 31 August 2025

In approving these financial statements as trustees of the company we hereby confirm:

(a) that for the year stated above the company was entitled to the exemption conferred by section 477 of the Companies Act 2006;

(b) that no notice has been deposited at the registered office of the company pursuant to section 476 of the Companies Act 2006 requesting that an audit be conducted for the year ended 31 August 2025.


(c) that we acknowledge our responsibilities for:

(1) ensuring that the company keeps proper accounting records which comply with section 386 of the Companies Act 2006, and

(2) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its surplus or deficit for the year then ended in accordance with the requirements of sections 394 and 395, and which otherwise comply with the provisions of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

These financial statements are prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the board on 29 June 2026 and signed on its behalf by



Dr Fiona Regan
Treasurer, Trustee

Registration number 07003983

The notes on pages 17 to 22 form an integral part of these financial statements.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2025

1. Accounting policies

The principal accounting policies are summarised below. The accounting policies have been applied consistently throughout the year and the preceding year.

1.1. Basis of accounting

The financial statements have been prepared in accordance with Accounting and reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

British Society For Paediatric Endocrinology and Diabetes meets the definition of a public benefit entity under FRS 102.

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

The trustees consider that there are no material uncertainties about the Trust's ability to continue as a going concern.

For the reporting year the charity has updated the presentation of some of its categories of income and expenditure so as to better reflect its current operations. Where relevant the comparative amounts have also been aligned to this presentation. This has had no impact on the reported surplus or net asset position for the current or comparative year.

The financial statements are presented in sterling which is the functional currency of the charity.

1.2. Cashflow

The charity has taken advantage of the exemption in FRS102 from the requirement to produce a cashflow statement because it is a small charity.

1.3. Incoming resources

All incoming resources are included in the statement of financial activities when the charity is entitled to the income and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income:

Voluntary income is received by way of grants, donations and gifts and is included in full in the statement of financial activities when receivable. Grants where entitlement is not conditional on the delivery of a specific performance by the charity, are recognised when the charity becomes unconditionally entitled to the grant.

Donated services and facilities are included at the value to the charity where this can be quantified. The value of services provided by volunteers has not been included.

Gifts donated for resale are included as incoming resources within activities for generating funds when they are sold.

Income from investments is included in the year in which it is receivable.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2025

1.4. Resources expended

Expenditure is recognised on an accrual basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is reported as part of the expenditure to which it relates.

Costs of generating funds comprise the costs associated with attracting voluntary income and the costs of trading for fundraising purposes including the charity's shop.

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Support costs are those costs incurred directly in support of expenditure on the objects of the charity and include project management.

1.5. Leasing

Assets obtained under hire purchase contracts and finance leases are capitalised as tangible assets and depreciated over the shorter of the lease term and their useful lives. Obligations under such agreements are included in creditors net of the finance charge allocated to future periods. The finance element of the rental payment is charged to the profit and loss account so as to produce constant periodic rates of charge on the net obligations outstanding in each period.

2. Activities for generating funds

	Unrestricted funds £	2025 Total £	2024 Total £
Sponsor Income	53,445	53,445	108,500
Membership Subscriptions	39,160	39,160	48,665
Annual Meeting Income	269,701	269,701	214,899
	<u>362,306</u>	<u>362,306</u>	<u>372,064</u>

3. Income from investments

	Unrestricted funds £	2025 Total £	2024 Total £
Bank interest receivable	16,742	16,742	21,462
	<u>16,742</u>	<u>16,742</u>	<u>21,462</u>

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2025

4. Cost of generating funds

	Unrestricted funds £	2025 Total £	2024 Total £
Secretariat fees	53,249	53,249	46,978
Website expenditure	11,159	11,159	10,642
Sponsor commission	14,027	14,027	5,550
Credit card charges	-	-	1,644
Sundry expenses	3,257	3,257	1,133
	<u>81,692</u>	<u>81,692</u>	<u>65,947</u>

5. Expenditure on charitable activities - by fund type

	Unrestricted funds £	2025 Total £	2024 Total £
Annual meeting	217,417	217,417	220,086
Training	1,500	1,500	15,850
Research	58,000	58,000	33,300
	<u>276,917</u>	<u>276,917</u>	<u>269,236</u>

6. Expenditure on charitable activities - by activity

	Activities undertaken directly £	Grant funding activities £	Support costs £	2025 Total £	2024 Total £
Annual meeting	212,356	3,800	1,261	217,417	220,086
Training	-	15,850	-	1,500	15,850
Research	-	33,300	-	58,000	33,300
	<u>212,356</u>	<u>52,950</u>	<u>1,261</u>	<u>276,917</u>	<u>269,236</u>

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2025

7. Other

	Unrestricted funds £	2025 Total £	2024 Total £
Accountancy- monthly bookkeeping	3,564	3,564	3,366
Accountancy - yearly financial statements	2,268	2,268	2,268
Insurance	-	-	1,186
Bank charges	9	9	75
	<u>5,841</u>	<u>5,841</u>	<u>6,895</u>

8. Analysis of support costs

	Annual meeting £	2025 Total £	2024 Total £
Travel expenses	1,261	1,261	177
	<u>1,261</u>	<u>1,261</u>	<u>177</u>

9. Employees

There were no employees during the year.

No salaries or wages have been paid to the trustees during the year.

10. Taxation

The charity's activities fall within the exemptions afforded by the provisions of Part 10 Income Tax Act 2007 or Section 256 of the Taxation of Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects. Accordingly, there is no taxation charge in these accounts.

11. Debtors

	2025 £	2024 £
Other debtors	24,636	25,975
Prepayments and accrued income	8,000	11,106
	<u>32,636</u>	<u>37,081</u>

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2025

12. Creditors: amounts falling due within one year

	2025	2024
	£	£
Accruals and deferred income	23,295	32,566
	<u>23,295</u>	<u>32,566</u>

13. Analysis of net assets between funds

	Unrestricted funds	Total funds
	£	£
Fund balances at 31 August 2025 as represented by:		
Current assets	1,101,288	1,101,288
Current liabilities	(23,295)	(23,295)
	<u>1,077,993</u>	<u>1,077,993</u>

14. Unrestricted funds

	Opening funds	Incoming resources	Outgoing resources	At 31 August 2025
	£	£	£	£
General reserves	1,063,395	379,048	(364,450)	1,077,993
	<u>1,063,395</u>	<u>379,048</u>	<u>(364,450)</u>	<u>1,077,993</u>

Purposes of unrestricted funds

The purpose of the unrestricted funds is to advance education in paediatric endocrinology and related subjects by promoting research and disseminating the useful results of such research.

15. Restricted funds

	Opening funds	At 31 August 2025
	£	£
Restricted funds	-	-
	<u>-</u>	<u>-</u>

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2025

16. Company limited by guarantee

British Society For Paediatric Endocrinology and Diabetes is a company limited by guarantee and accordingly does not have a share capital.

Every member of the company undertakes to contribute such amount as may be required not exceeding £1 to the assets of the charitable company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

Accounts

Charity number: 1135319
Company number: 07003983

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Trustees' annual report and financial statements

for the year ended 31 August 2024

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Contents

	Page
Legal and administrative information	1
Trustees' annual report	2 - 10
Independent examiners' report	11
Statement of financial activities	12
Balance sheet	13 - 14
Notes to the financial statements	15 - 20

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Legal and administrative information

Charity registration number 1135319

Company registration number 07003983

Business address c/o Paediatric Endocrine Department
E Floor Martin Wing
Leeds Children's Hospital
Leeds
LS1 3EX

Registered office c/o RWK Goodman LLP
69 Carter Lane
London
England
EC4V 5EQ

Trustees Dr Fiona Regan (appointed 9 November 2023)
Dr Sabah Alvi (resigned 9 November 2023)
Dr Tabitha Randell (resigned 9 October 2024)
Dr Melanie Kershaw (resigned 9 October 2024)
Dr Talat Mushtaq (appointed 9 October 2024)
Dr Senthilkumar Karuppanansenniappan (appointed 9 October 2024)

Accountants Leftley Rowe & Company
Second Floor
87 Kenton Road
Harrow
Middlesex
HA3 0AH

Bankers Lloyds Bank Plc
Kings Heath
32 - 34 Alcester Road South
Kings Heath
Birmingham
B14 7PU

British Society For Paediatric Endocrinology and Diabetes

(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report) for the year ended 31 August 2024

The trustees present their report and the financial statements of the charity for the year ended 31 August 2024. The trustees have adopted the provisions of the Statement of Recommended Practice (SORP) 'Accounting and Reporting by Charities' (FRS 102) in preparing the annual report and financial statements of the charity. The directors of the charitable company are its trustees for the purposes of charity law. The directors who served during the year and up to the date of this report are set out on page 1.

Structure, governance and management

The British Society For Paediatric Endocrinology and Diabetes is constituted by a Deed of Trust and is a registered charity No 1135319. The charity changed its status to a company limited by guarantee from 01 September 2010.

Objectives and activities

The aims of the charity are to advance education in paediatric endocrinology and related subjects by promoting research and disseminating the useful results of such research.

In keeping with the aims, the Society shall have the following powers:

1. To arrange and provide for the holding of meetings, lectures and seminars.
2. To procure to be written and print, publish, issue and circulate gratuitously or otherwise such papers, periodicals, pamphlets or other documents.
3. To raise funds and to invite and receive contributions from any person or persons whatsoever by way of subscriptions and otherwise provided that the Society shall not undertake any permanent trading activities in raising funds for its primary charitable objectives.
4. To cooperate, associate or affiliate with any other charitable institutions.
5. To do all such other lawful things as are necessary for the attainment of the above objectives.

The charity has 522 elected members, who include doctors, scientists, allied professionals (specialist nurses, pharmacists and dietitians) and medical students. This has been a significant increase on last year. During 2023-2024, the Society has been active in presenting clinical and basic research in the field of paediatric endocrinology and diabetes, both to its own members and the wider paediatric community.

Members of the society are represented on committees with other related societies to ensure close liaison, and paediatric endocrinology representation in the drawing up of guidelines. Examples include NICE, European Endocrine Reference Network (Endo ERN), European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA), Diabetes UK, CYP Diabetes Board, Society for Endocrinology and ACDC.

The charity works closely with national agencies for paediatrics and is affiliated with the Royal College of Paediatrics and Child Health, British Endocrine Society, Royal College of Physicians and the Society for Endocrinology. The society also works closely with Patient Support Groups, such as The Child Growth Foundation, The Turner Society Support Group, British Thyroid Foundation, Pituitary Foundation and Living with CAH.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2024

Major areas of activity in support of these objectives

In October 2024 we held our annual meeting in Glasgow. It was well attended and delivered an excellent scientific programme with a wide range of topics covering the depth and breadth of paediatric endocrinology and diabetes delivered by renowned speakers, including many local delegates from the adult and paediatric endocrine community. The BSPED 2024 Awards Session was held on the second day of the meeting in which the Plenary talk by the James M Tanner Award winner was delivered by Dr Nick Shaw, detailing his journey throughout his career. Dr Shaw's work in the arena of bone endocrinology has become ever more prevalent and recognised as an important endocrine sub speciality over the last decade.

Other highlights included

- o Expert talks/symposia (x 6) delivered by expert speakers
- o Parallel endocrinology and diabetes sessions
- o Personal Practice session and 4 Satellite Symposia
- o Presentations from previous year's BSPED Award winners
- o BSPED 2024 Awards Session
- o Top scoring abstracts as oral communications
- o Guided poster tours
- o CME day including interesting case presentations
- o Nurse and Endocrine Professionals Session
- o How do I? sessions (endocrine & diabetes)

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2024

Key activity 2023-2024

Virtual Paediatric Endocrine Group (VPEG)

- " Managed by Senthil Senniappan as POC Chair and supported by Dinesh Giri as CME Officer
- " Popular quarterly case presentation sessions with up to 70 people registering for the meetings in 2023

Awards and grants

Overseen by the Awards Committee: Nadia Amin (Chair), Executive Committee members and Clinical Committee Chair

Current Grants and awards

- " Research & Innovation Award
- " Paediatric Endocrine & Diabetes Nurse & AHP Awards
- " James M Tanner Award (Nominations for 2025 will open following this meeting)
- " Conference Travel Grants

Peer Review

- " BSPED now running a virtual peer review process with a number of reviews taking place in 2024 including Leicester, Leeds, Edinburgh and Glasgow

Support for LSBU masters course for nurses

- " BSPED funded 10 Nurses in 2024 to complete this nurse endocrine masters module

Home Office Age Estimation Scientific Advisory Committee

- " BSPED chair part of interim committee
- " Tabitha Randell appointed to ongoing committee Dec 2022

NHSE Out-patient Recovery and Transformation Programme

- " BSPED chair represented RCPCH on programme
- RCPCH - BSPED been working closely with them on other project

Grant and Project funding for 2025 and beyond

- " BSPED now actively seeking ideas and suggestions from its members for projects to fund in coming years.
 - " The key criteria for any project is that it would bring benefit to BSPED and the wider Endocrine Community
- Membership Fees in 2024
- " BSPED fees increased by 5% to a still very reasonable £126 per year
 - " BSPED membership includes a number of benefits.

BSPED Clinical Studies Group

Diabetes (Diabetes UK)

- " 2024 priorities:
 - " Type 2 diabetes in children and young people - highlight notice
 - " Mental health and psychological impact in young people
 - " Improving Diabetes Education in educational settings
 - " Diabetes UK Project Grant funded 2024 commenced (Understanding Inequalities and Barriers to Accessing Diabetes Technology in Children and Young People with Type 1 Diabetes)
 - " Voice of the Child and Young Person in Diabetes Research 2024 - completed
 - " Publication: Bridging the digital divide
- Endocrine (NIHR)
- " No longer supported by NIHR due to CRN restructure
 - " Discussions regarding BSPED retaining a research focus
 - " The plan is to set this up as a Research Special Interest Group

**British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)**

**Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2024**

Priorities identified for workplan in 2024

1. Streamlining development of BSPED standards and guidelines
2. Guidance on development of BSPED patient information leaflets.
3. BSPED AI steroid card translations and educational standards of paediatric AI
4. Contributions to key NICE consultations: eg: Teplizumab; review of AI guidance
5. Re-launch of GH Audit
6. Honing peer review process
7. Reviewing SIGs and terms of reference
8. BSPED Pre-type 1 diabetes group set up

Royal College of Paediatrics and Child Health Annual Professional Meeting 2024

- o 27th March 2024: Face to face BSPED special interest group symposium
- o Combined session with British Paediatric and Adolescent Bone Group
- o 4 guest speakers and 5 oral communications
- o 30 abstracts submitted: 1 invited guest lecture, 3 oral presentations at symposia, 3 as short poster presentations, 24 as eposters

Summary of Clinical Committee Activity 2023-24

The Clinical Committee continues to be very productive and meets regularly in remote format which enables good attendance.

Commissioning Paediatric Diabetes & Endocrinology: No change to Wales, NI & Scotland-England-NHSE Service Specification for Paediatric Endocrinology should be published shortly.

Achievements

Guideline, standards and position statements

Statement on use of GnRH analogue

Review of testosterone guidance

BSPED standards of paediatric endocrine services (update review)

Contributed to

Surveys: Disordered breathing in PWS, fertility preservation in PWS, use of electronic growth chart (Growth SIG-ethics approved)

NICE guideline: Adrenal insufficiency, T1DM retinopathy

NICE review: Vamorolone and Givinostat in DMD, NICE methods and process manual consultation

Adrenal insufficiency achievements

Paediatric Adrenal Insufficiency steroid card translation: Polish, Turkish, Greek, Urdu, Romanian already available.

Arabic, Chinese, Slovakian (Awaiting second reviewer)

BSPED Paediatric Endocrine Nurse Specialist Competency Developmental Framework (Peter Laing, Karen Thompson)

BSPED working group on standards of education of paediatric adrenal insufficiency

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2024

Committee membership

Jarod Wong - Chair; clinical committee
Rachel Wright: Diabetes Nurse Representative
Nabil Boulous: Diabetes/Endocrine Allied Health Representative
Sarah McCarrison: Digital & Information Officer
Melanie Kershaw: Clinical Guidelines Officer
James Law: Clinical Standards Officer

Farewell to (completed terms of office):

Jennifer Calvert: Diabetes Nurse/Allied Health Representative
Angela Lucas-Herald: Digital & Information Officer
Pooja Sachdev: Clinical Standards Officer

Special Interest Groups

Growth Disorders	Helen Storr	2020-2025
Thyroid	Catherine Peters/Tim Cheetham	2020- 2025
DSD	Zainaba Mohamed	2016- 2025
CAH /adrenal	Nils Krone	2021-2025
HPAT	Paul Dimitri	2019- 2025
T2DM	Billy White/Pooja Sachdev	2019-2025

1. Growth disorders

National guidelines, clinical standards, and position statements:

- " Clinical Standards for rhIGF-I therapy for Severe Primary IGF-1 deficiency & severe insulin resistance
- " Position statement for the use of long acting hGH
- " Position statement 'Growth hormone therapy in Silver-Russell syndrome (SRS) between 2 and 4 years of age
- " Shared care guidelines for rhGH therapy (Updated)

National advisory roles:

- " Input & liaison with editorship of the BNFC to update and correct prescribing guidance for hGH for Noonan syndrome (BNFC-updated as a result)
- " Advisory role into eligibility criteria / content of Genomics England early growth failure diagnostic gene panel (panel & eligibility updated following SIG input)
- " Advisory role to newborn genome sequencing programme (advised which genes to be included and developed the validation strategy)

Research/audit:

- " National electronic growth chart audit - The SIG established a working group including GRID trainees, RCPCH representation and SIG members - ethics approval obtained (May 2024) and project ongoing

2. Thyroid

- " Regular interaction re secondary hypothyroidism detection (Cheetham, Law, Peters, Schoenmakers, Wood). Ethics approval and associated data collection / compilation ongoing

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2024

3. DSD

Audit

- " Completed Re-audit of BSPED DSD standards- to be presented at BSPED as Oral.

Learning

- " Shared learning from Case based discussion

QI/animation video

- " Commenced a QI project on DSD animation video- BCH (due to be presented in the next SIG meeting)

4. Adrenal/CAH

- o Ongoing project on real world data collection of patients with CAH (now 14 UK centres) - presentation of prelim results at BSPED 2024
- o Support and UK link to ENS@T adrenal tumours in children and young persons
- o Feedback to NICE guideline on adrenal insufficiency: identification and management

5. HPAT

- " Publication of first UK national paediatric craniopharyngioma guideline in Lancet Diabetes & Endocrinology
- " Opening of phase 3 randomised controlled trial for the use of setmelanotide in the use of acquired hypothalamic obesity at GOSH and Birmingham
- " Increased international interest in HPAT - Chile, Mexico, Netherlands, Estonia, Czech Republic
- " 13 year analysis of HPAT outcomes now in progress
- " Collaboration with Princess Maxima Centre (Utrecht) to look at outcomes of optic pathway glioma patients with GH/IGF-1 abnormalities
- " Members participating in various for a - ESPE Science Symposium on Hypothalamic Dysfunction in Childhood, International Postgraduate Course in Childhood Craniopharyngioma, Endo-ERN Webinar on Hypothalamic Obesity in Craniopharyngiomas
- " In progress - long awaited 1st UK HPAT Clinical Study Day - date finalised 13 March 2024

6. T2DM SIG

- " Providing education to HCPs. National Study Day on 24 April was attended by over 500 people.
- " Implementing Network-based HCP Peer Support Networks for T2 diabetes in England in line with NHSE focus area. Ensuring regional T2 Networks are in place and sharing learning within the national working group. Discussing challenges, good practice and outputs. Supporting adoption across the 4-Nations
- " Promoting ELFH T2 diabetes training modules
- " Development of Task and Finish groups in key areas: First Year of Care; Guidelines; School Health Care Plan; Patient Information Leaflets.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2024

Plans for 2024-2025

- o Streamlining development of BSPED standards and guidelines
- o Guidance on development of BSPED patient information leaflets
- o BSPED AI steroid card translations
- o Educational standards of paediatric AI
- o Google Analytics to review website engagement
- o BSPED LinkedIn presence
- o Contributions to key NICE consultations: Teplizumab; review of AI guidance, etc
- o Re-launch of GH Audit
- o Honing peer review process
- o Reviewing SIGs and terms of reference

Diabetes

DKA calculator

Dan Leach creator- being updated

NICE

- o Teplizumab - scoping consultation - [ID6259]- in progress
 - o Retinopathy [NG242] - Aug 2024
- NHS Safety team - patient safety
- Representation on NHSE Oversight group
- o HCL 5-year plan- commenced April 2024
 - o GIRFT reviews

Pre-Type 1 diabetes group (12 members / 4 nations)

BSPED Website Development

The BSPED website was re-developed and launched in January 2018 and continues to be maintained by BSPED committee members.

The website is aimed at:

- Providing up-to-date useful & relevant information to encourage usage of the site by health professionals as well as patients/carers
- Facilitating communication & collaboration among BSPED members
- Promoting our specialty and society nationally and internationally
- Providing a user friendly e.g. smart phone friendly version

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2024

Other supported activities

The Society supported a number of other activities in 2023 - 2024 which included:

- " Updating UK standards for paediatric endocrinology (April 2024)
- " On going support to the maintenance of the BSPED Website re-development (total cost of £10,642)
- " Funded Masters nursing courses in Paediatric Endocrinology, London Southbank University (£12,850). This takes place every 2 years and we have committed to ongoing funding for the next round in 2024-26
- " Collaboration with a medical journal (Endocrinology, Diabetes and Metabolism case reports) for members to publish their research at a reduced rate
- " Travel and attendance grants for junior members presenting their research work at annual conferences to the sum of £7,101
- " Educational prizes / research awards of £33,300

Sponsors

There is dedicated financial support to the Society from sponsors from the pharmaceutical industry. In 2024 the partnership, sponsorship and engagement opportunities were modernised and stratified into individual components replacing the previous 4 tiers of support with different levels of benefits within each tier. Items throughout the year available for purchase include member webinar/email/newsletter advertising/section of the partner resource library. Annual meetings opportunities include satellite symposium/exhibitor/lanyard logo/delegate bag logo. The majority of the sponsored funding is to support the Annual Meeting, growth hormone audit, research grant and educational training sessions for doctors and nurses. Some of the funding is used for Clinical Committee, Executive Committee and Clinical Special Interest Group activities. Funding also contributes to the running of the Society and Secretariat fees.

Financial review

It is the policy of the Society to maintain unrestricted funds, which are the free reserves of the charity. The reserves are held at a level that ensures the future financial viability of the Society. That level is deemed to be one that equates to a minimum of approximately one year's expenditure. Note 14 of the financial statements indicates that there are £1,063,395 unrestricted funds as at 31 August 2024. This provides sufficient funds to cover management, administration and support costs.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2024

Statement of trustees' responsibilities

The trustees are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Generally Accepted Accounting Practice.

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and which enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Small company provisions

This report has been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

This report was approved by the Board on 29 June 2025 and signed on its behalf by



Dr Fiona Regan
Treasurer

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Independent examiner's report to the trustees on the unaudited financial statements of British Society For Paediatric Endocrinology and Diabetes.

I report to the charity trustees on my examination of the financial statements of British Society For Paediatric Endocrinology and Diabetes for the year ended 31 August 2024 set out on pages 12 to 20.

Responsibilities and basis of report

As the charity trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the financial statements of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your company's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in accordance with section 386 of the Companies Act 2006; or
2. the financial statements do not accord with such records; or
3. the financial statements do not comply with relevant accounting requirements under section 396 of the Companies Act 2006 other than any requirement that the financial statements give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the financial statements have not been prepared in accordance with the Charities SORP (FRS102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Christopher Andrews ACA
Independent examiner

Leftley Rowe & Company
Chartered Accountants and Statutory Auditors
Second Floor
87 Kenton Road
Harrow
Middlesex
HA3 0AH

29 June 2025

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Statement of financial activities (incorporating the income and expenditure account)

For the year ended 31 August 2024

	Notes	Unrestricted funds £	2024 Total £	2023 Total £
Income				
Incoming resources from generating funds:				
Activities for generating funds	2	372,064	372,064	327,860
Income from investments	3	21,462	21,462	4,646
Total income		<u>393,526</u>	<u>393,526</u>	<u>332,506</u>
Expenditure				
Costs of generating funds:				
Cost of generating funds	4	65,947	65,947	61,357
Expenditure on charitable activities	5	269,236	269,236	218,572
Other	7	6,895	6,895	7,613
Total expenditure		<u>342,078</u>	<u>342,078</u>	<u>287,542</u>
Net movement in funds		51,448	51,448	44,964
Reconciliation of funds				
Total funds brought forward		1,011,947	1,011,947	966,983
Total funds carried forward		<u>1,063,395</u>	<u>1,063,395</u>	<u>1,011,947</u>

The statement of financial activities includes all gains and losses in the year and therefore a separate statement of total recognised gains and losses has not been prepared.

All of the above amounts relate to continuing activities.

The notes on pages 15 to 20 form an integral part of these financial statements.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Balance sheet
as at 31 August 2024

	Notes	£	2024 £	2023 £
Current assets				
Debtors	11	37,081		35,702
Cash at bank and in hand		1,058,880		989,566
		<u>1,095,961</u>		<u>1,025,268</u>
Creditors: amounts falling due within one year	12	<u>(32,566)</u>		<u>(13,321)</u>
Net current assets			<u>1,063,395</u>	<u>1,011,947</u>
Net assets			<u>1,063,395</u>	<u>1,011,947</u>
Charity Funds				
Unrestricted funds	14		<u>1,063,395</u>	<u>1,011,947</u>
Total funds			<u>1,063,395</u>	<u>1,011,947</u>

The Balance Sheet continues on the following page.

The notes on pages 15 to 20 form an integral part of these financial statements.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Balance sheet (continued)

Trustees statements required by the Companies Act 2006
for the year ended 31 August 2024

In approving these financial statements as trustees of the company we hereby confirm:

(a) that for the year stated above the company was entitled to the exemption conferred by section 477 of the Companies Act 2006;

(b) that no notice has been deposited at the registered office of the company pursuant to section 476 of the Companies Act 2006 requesting that an audit be conducted for the year ended 31 August 2024.

(c) that we acknowledge our responsibilities for:

(1) ensuring that the company keeps proper accounting records which comply with section 386 of the Companies Act 2006, and

(2) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its surplus or deficit for the year then ended in accordance with the requirements of sections 394 and 395, and which otherwise comply with the provisions of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

These financial statements are prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the board on 29 June 2025 and signed on its behalf by



Dr Fiona Regan
Treasurer, Trustee

Registration number 07003983

The notes on pages 15 to 20 form an integral part of these financial statements.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2024

1. Accounting policies

The principal accounting policies are summarised below. The accounting policies have been applied consistently throughout the year and the preceding year.

1.1. Basis of accounting

The financial statements have been prepared in accordance with Accounting and reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

British Society For Paediatric Endocrinology and Diabetes meets the definition of a public benefit entity under FRS 102.

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

The trustees consider that there are no material uncertainties about the Trust's ability to continue as a going concern.

For the reporting year the charity has updated the presentation of some of its categories of income and expenditure so as to better reflect its current operations. Where relevant the comparative amounts have also been aligned to this presentation. This has had no impact on the reported surplus or net asset position for the current or comparative year.

The financial statements are presented in sterling which is the functional currency of the charity.

1.2. Cashflow

The charity has taken advantage of the exemption in FRS102 from the requirement to produce a cashflow statement because it is a small charity.

1.3. Incoming resources

All incoming resources are included in the statement of financial activities when the charity is entitled to the income and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income:

Voluntary income is received by way of grants, donations and gifts and is included in full in the statement of financial activities when receivable. Grants where entitlement is not conditional on the delivery of a specific performance by the charity, are recognised when the charity becomes unconditionally entitled to the grant.

Donated services and facilities are included at the value to the charity where this can be quantified. The value of services provided by volunteers has not been included.

Gifts donated for resale are included as incoming resources within activities for generating funds when they are sold.

Income from investments is included in the year in which it is receivable.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2024

1.4. Resources expended

Expenditure is recognised on an accrual basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is reported as part of the expenditure to which it relates.

Costs of generating funds comprise the costs associated with attracting voluntary income and the costs of trading for fundraising purposes including the charity's shop.

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Support costs are those costs incurred directly in support of expenditure on the objects of the charity and include project management.

1.5. Leasing

Assets obtained under hire purchase contracts and finance leases are capitalised as tangible assets and depreciated over the shorter of the lease term and their useful lives. Obligations under such agreements are included in creditors net of the finance charge allocated to future periods. The finance element of the rental payment is charged to the profit and loss account so as to produce constant periodic rates of charge on the net obligations outstanding in each period.

2. Activities for generating funds

	Unrestricted funds £	2024 Total £	2023 Total £
Sponsor Income	108,500	108,500	128,593
Membership Subscriptions	48,665	48,665	41,346
Annual Meeting Income	214,899	214,899	157,921
	<u>372,064</u>	<u>372,064</u>	<u>327,860</u>

3. Income from investments

	Unrestricted funds £	2024 Total £	2023 Total £
Bank interest receivable	21,462	21,462	4,646
	<u>21,462</u>	<u>21,462</u>	<u>4,646</u>

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2024

4. Cost of generating funds

	Unrestricted funds £	2024 Total £	2023 Total £
Secretariat fees	46,978	46,978	41,607
Website expenditure	10,642	10,642	11,588
Sponsor commission	5,550	5,550	6,690
Credit card charges	1,644	1,644	1,028
Sundry expenses	1,133	1,133	444
	<u>65,947</u>	<u>65,947</u>	<u>61,357</u>

5. Expenditure on charitable activities - by fund type

	Unrestricted funds £	2024 Total £	2023 Total £
Annual meeting	220,086	220,086	209,583
Training	15,850	15,850	1,000
Research	33,300	33,300	7,989
	<u>269,236</u>	<u>269,236</u>	<u>218,572</u>

6. Expenditure on charitable activities - by activity

	Activities undertaken directly £	Grant funding activities £	Support costs £	2024 Total £	2023 Total £
Annual meeting	212,508	7,401	177	220,086	209,583
Training	-	15,850	-	15,850	1,000
Research	-	33,300	-	33,300	7,989
	<u>212,508</u>	<u>56,551</u>	<u>177</u>	<u>269,236</u>	<u>218,572</u>

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2024

7. Other

	Unrestricted funds	2024 Total	2023 Total
	£	£	£
Accountancy- monthly bookkeeping	3,366	3,366	3,960
Accountancy - yearly financial statements	2,268	2,268	2,520
Insurance	1,186	1,186	1,133
Bank charges	75	75	-
	<u>6,895</u>	<u>6,895</u>	<u>7,613</u>

8. Analysis of support costs

	Annual meeting	2024 Total	2023 Total
	£	£	£
Travel expenses	177	177	-
	<u>177</u>	<u>177</u>	<u>-</u>

9. Employees

There were no employees during the year.

No salaries or wages have been paid to the trustees during the year.

10. Taxation

The charity's activities fall within the exemptions afforded by the provisions of Part 10 Income Tax Act 2007 or Section 256 of the Taxation of Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects. Accordingly, there is no taxation charge in these accounts.

11. Debtors

	2024 £	2023 £
Other debtors	25,975	24,397
Prepayments and accrued income	11,106	11,305
	<u>37,081</u>	<u>35,702</u>

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2024

12. Creditors: amounts falling due within one year

	2024	2023
	£	£
Accruals and deferred income	32,566	13,321

13. Analysis of net assets between funds

	Unrestricted funds	Total funds
	£	£
Fund balances at 31 August 2024 as represented by:		
Current assets	1,095,961	1,095,961
Current liabilities	(32,566)	(32,566)
	<u>1,063,395</u>	<u>1,063,395</u>

14. Unrestricted funds

	Opening funds	Incoming resources	Outgoing resources	At 31 August 2024
	£	£	£	£
General reserves	<u>1,011,947</u>	<u>393,526</u>	<u>(342,078)</u>	<u>1,063,395</u>

Purposes of unrestricted funds

The purpose of the unrestricted funds is to advance education in paediatric endocrinology and related subjects by promoting research and disseminating the useful results of such research.

15. Restricted funds

	Opening funds	At 31 August 2024
	£	£
Restricted funds	<u>-</u>	<u>-</u>

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2024

16. Company limited by guarantee

British Society For Paediatric Endocrinology and Diabetes is a company limited by guarantee and accordingly does not have a share capital.

Every member of the company undertakes to contribute such amount as may be required not exceeding £1 to the assets of the charitable company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

Accounts

Charity number: 1135319
Company number: 07003983

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Trustees' annual report and financial statements
for the year ended 31 August 2023

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Contents

	Page
Legal and administrative information	1
Trustees' annual report	2 - 10
Independent examiners' report	11
Statement of financial activities	12
Balance sheet	13 - 14
Notes to the financial statements	15 - 19

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Legal and administrative information

Charity registration number 1135319

Company registration number 07003983

Business address c/o Paediatric Endocrine Department
E Floor Martin Wing
Leeds Children's Hospital
Leeds
LS1 3EX

Registered office c/o RWK Goodman LLP
69 Carter Lane
London
England
EC4V 5EQ

Trustees Dr Sabah Alvi, Treasurer (resigned 9 November 2023)
Dr Fiona Regan, Treasurer (appointed 9 November 2023)
Dr Tabitha Randell, Chairperson
Dr Melanie Kershaw, Secretary

Accountants Leftley Rowe & Company
Second Floor
87 Kenton Road
Harrow
Middlesex
HA3 0AH

Bankers Lloyds Bank Plc
Kings Heath
32 - 34 Alcester Road South
Kings Heath
Birmingham
B14 7PU

British Society For Paediatric Endocrinology and Diabetes

(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report) for the year ended 31 August 2023

The trustees present their report and the financial statements of the charity for the year ended 31 August 2023. The trustees have adopted the provisions of the Statement of Recommended Practice (SORP) 'Accounting and Reporting by Charities' (FRS 102) in preparing the annual report and financial statements of the charity. The directors of the charitable company are its trustees for the purposes of charity law. The directors who served during the year and up to the date of this report are set out on page 1.

Structure, governance and management

The British Society For Paediatric Endocrinology and Diabetes is constituted by a Deed of Trust and is a registered charity No 1135319. The charity changed its status to a company limited by guarantee from 01 September 2010.

Objectives and activities

The aims of the charity are to advance education in paediatric endocrinology and related subjects by promoting research and disseminating the useful results of such research.

In keeping with the aims, the Society shall have the following powers:

1. To arrange and provide for the holding of meetings, lectures and seminars.
2. To procure to be written and print, publish, issue and circulate gratuitously or otherwise such papers, periodicals, pamphlets or other documents.
3. To raise funds and to invite and receive contributions from any person or persons whatsoever by way of subscriptions and otherwise provided that the Society shall not undertake any permanent trading activities in raising funds for its primary charitable objectives.
4. To cooperate, associate or affiliate with any other charitable institutions.
5. To do all such other lawful things as are necessary for the attainment of the above objectives.

The charity has 564 elected members, who include doctors, scientists, allied professionals (specialist nurses, pharmacists and dietitians) and medical students. This has been a significant increase on last year. During 2022-2023, the Society has been active in presenting clinical and basic research in the field of paediatric endocrinology and diabetes, both to its own members and the wider paediatric community.

Members of the society are represented on committees with other related societies to ensure close liaison, and paediatric endocrinology representation in the drawing up of guidelines. Examples include NICE, European Endocrine Reference Network (Endo ERN), European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA), Diabetes UK, CYP Diabetes Board, Society for Endocrinology and ACDC.

The charity works closely with national agencies for paediatrics and is affiliated with the Royal College of Paediatrics and Child Health, British Endocrine Society, Royal College of Physicians and the Society for Endocrinology. The society also works closely with Patient Support Groups, such as The Child Growth Foundation, The Turner Society Support Group, British Thyroid Foundation, Pituitary Foundation and Living with CAH.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2023

Major areas of activity in support of these objectives

In 2023 we held our annual meeting in Manchester. This was a landmark meeting as it celebrated 50 years of our Society. It was well attended and delivered an excellent scientific programme with a wide range of topics covering the depth and breadth of paediatric endocrinology and diabetes delivered by renowned speakers, including a special guest speaker Dr Nancy Crimmins from the United States, who gave a key note lecture on the American experience of paediatric obesity.

The BSPED 2023 Awards Session was held on the second day of the meeting in which the Plenary talk by the James M Tanner Award winner was delivered by Dr Malcolm Donaldson, giving a fascinating insight into the life and works of one of the Society's luminaries. He is now almost as famous for his accompanying musical act with his wife Julia, creator of the Gruffalo, as he is for his four decades of paediatric medicine!

Other highlights included

- o Expert talks/symposia (x 6) delivered by expert speakers
- o Parallel endocrinology and diabetes sessions
- o Personal Practice session and 4 Satellite Symposia
- o Presentations from previous year's BSPED Award winners
- o BSPED 2023 Awards Session
- o Top scoring abstracts as oral communications (x 39)
- o Guided poster tours (x10 per day)
- o CME day including interesting case presentations
- o Nurse and Endocrine Professionals Session
- NEW
- o How do I? sessions (endocrine & diabetes)
- o Debate
- o International Speaker

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2023

Key activity 2022-2023

Virtual Paediatric Endocrine Group (VPEG)

- " Managed by Senthil Senniappan as POC Chair and supported by Dinesh Giri as CME Officer
- " Popular quarterly case presentation sessions with up to 70 people registering for the meetings in 2023

Awards and grants

Overseen by the Awards Committee: Nadia Amin (Chair), Executive Committee members and Clinical Committee Chair

Current Grants and awards

- " Research & Innovation Award
- " Paediatric Endocrine & Diabetes Nurse & AHP Awards
- " James M Tanner Award (Nominations for 2024 will open following this meeting)
- " Conference Travel Grants

Peer Review

- " BSPED now running a virtual peer review process with a number of reviews taking place in early 2024

Support for LSBU masters course for nurses

- " Nurses endocrine masters module will be held again at LSBU in 2024
- " BSPED will fund 10 Nurses to complete this biannual course

Home Office Age Estimation Scientific Advisory Committee

- " BSPED chair part of interim committee
- " Tabitha Randell appointed to ongoing committee Dec 2022

NHSE Out-patient Recovery and Transformation Programme

- " BSPED chair represented RCPCH on programme
- RCPCH - BSPED been working closely with them on other project

Grant and Project funding for 2024 and beyond

- " BSPED now actively seeking ideas and suggestions from its members for projects to fund in coming years.
- " The key criteria for any project is that it would bring benefit to BSPED and the wider Endocrine Community

Membership Fees in 2024

- " BSPED fees have remained static for several years to keep membership affordable in the post covid period. To ensure the continuation of the good work of the society, fees in 2024 will be subject to review and a likely moderate increase.
- " BSPED membership includes a number of benefits.

BSPED Clinical Studies Group

- " Active group discussing UK-wide potential studies (e.g. clinical trial of thyrotoxicosis) + ideas generation (website/registry/SIGs)
- " Participation from research active clinicians (including trainees) + patient group representatives
- " Supporting NIHR in endo rare disease study prioritization
- " Facilitating Neonatal WGS screening program
- " Supporting NIHR + RCPCH in national research programs
- " Advocating and supporting trainee research
- " Awaiting decision by NIHR on future logistic support for paed endo CSG

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2023

Priorities identified for workplan in 2023

1. Identifying barriers to technology uptake
2. Mental health and psychological impact in young people
3. Establishing how to best involve children and young people in research

Diabetes UK Project Grant funded 2023

UNBIASED: Understanding Inequalities and Barriers to Accessing Diabetes Technology in Children and Young People with Type 1 Diabetes.-(Chief Investigator Prof May Ng)- project commenced Oct 2023

Voice of the Child and Young Person in Diabetes Research 2023

Methodology: 6x focus groups to better understand the lived experiences of children and young people living with diabetes Aim: To systematically collect insights from children and young people into what matters most to them for future research to improve physical, psychological, and social outcomes living with diabetes.

Total number of workshop participants N= 24-36 participants (Study completed Sept 2023-Results pending for publication).

Royal College of Paediatrics and Child Health Annual Professional Meeting 2022

- o 24th May - Face to face BSPED special interest group symposium
- o Combined session with British Paediatric and Adolescent Bone Group
- o 4 guest speakers and 5 oral communications
- o 41 abstracts submitted: 4 oral presentations at the symposium, 35 as ePosters

Summary of Clinical Committee Activity 2022-23

The Clinical Committee continues to be very productive and meets regularly in remote format which enables good attendance.

Commissioning Paediatric Diabetes & Endocrinology: No change to Wales, NI & Scotland. England - NHSE Service Specification for Paediatric Endocrinology should be published shortly.

All areas are under review during 2024.

Achievements

New items

- o BSPED social media - 19% increase in X followers (total 1,642) and Facebook (total 3,899)
- o Paediatric Adrenal Insufficiency: full publication / website / materials - package of care
- o Updated parts of website and patient information leaflets

Guideline , standards and position statements

- o As per SIG updates

Contributed to

- o Surveys: PTEN thyroid cancer, Klinefelter, Pre-type 1 diabetes
- o NICE: diabetes, obesity (semaglutide), transition

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2023

Committee membership

- o Ewa Lichtarowicz-Krynska - DGH officer
- o Christine Desmond - Nursing officer
- o Katherine Hawton - CSAC / BSPED trainee representative
- o Rachel Wright and Nabil Boulos - Diabetes Nurse/ AHP officer
- o Jarod Wong - Chair; clinical committee

Outgoing, completed terms of office:

- o Fiona Regan - DGH representative
- o Isabel Sharratt - nursing officer
- o Jennifer Calvert - diabetes nurse / AHP officer
- o Ranna Khairi - trainee representative

Special Interest Groups

Growth Disorders	Helen Storr	2020-2024
Thyroid	Catherine Peters / Tim Cheetham	2020-2024
DSD	Zainaba Mohamed	2016-2025
CAH /adrenal	Nils Krone	2021-2024
HPAT	Paul Dimitri	2019-2023
T2DM	Billy White / Pooja Sachdev	2019-2023

1. Growth Disorders

- o Generated the following clinical standards:
- o BSPED Recommendations for initial clinical assessment, investigation and genetic testing of children with growth failure and/or short stature
- o BSPED Clinical standards for growth assessment and referral criteria for children with a suspected growth disorder
- o BSPED Recommendations for GH treatment of Growth Disorders in Childhood and Adolescence excluding GHD - awaiting endorsement by clinical committee
- o BSPED position statement
- o Growth hormone therapy in Silver-Russell syndrome (SRS) between 2 and 4 years of age
- o National activities:
- o NICE: long-acting GH draft consultation, Noonan's syndrome
- o BNFC - advising corrections and update for GH prescribing
- o NHSE growth related gene panels - provided review and update of composition of panels and eligibility criteria
- o Genomics England: Newborn Genomes Programme
- o In progress
- o Developing clinical standards for severe IGF-I deficiency
- o Review and update of BSPED shared care guidelines for GH therapy
- o Developing clinical standards for long-acting growth hormone therapy
- o Review of variation in provision and standardisation of electronic growth charts

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2023

2. Thyroid

- o Central CH and how to improve detection through newborn screening.
- o Reviewing screening methodology in other international centres and been working with the Newborn Genomes Programme.
- o Looking at how to collect 3 year outcome data for infants with primary CH and to work with local networks as needed
- o Evidence for routine TSH follow up in specific patient groups who have received iodine contrast media

3. DSD

- o Use of Prenatal Dexamethasone in Congenital Adrenal Hyperplasia (March 2023)
- o 2 SIG meetings this year; active peer participation and discussion (52 members). Ethically challenging case based discussion are held to support peer group.
- o NHSE service specification for DSD is awaited, highlighting changes in surgical management of DSD.
- o SIG invited CAH alliance to share their input
- o Shared learning: Presentations shared nationally from research overview: a single centre overview of 25 years' experience of DSD was presented in the summer SIG meeting
- o A proposal agreed for review and re audit of the DSD standards.

4. Adrenal/CAH

- o National service CAH evaluation
- o Submission of manuscript to Hormone Research in Paediatrics "National service evaluation of the quality of care for children and young people with congenital adrenal hyperplasia in the United Kingdom: survey responses from patients and clinicians"
- o Ongoing Discussion about Real World Data Collection vs Clinical Standards
- o Point of Contact for 100,000 genomes newborn screening and ongoing advice on adrenal conditions

5. HPAT

- o Publication of first UK national paediatric craniopharyngioma guideline in Lancet Diabetes & Endocrinology
- o Opening of phase 3 randomised controlled trial for the use of setmelanotide in the use of acquired hypothalamic obesity at GOSH and Birmingham
- o Increased international interest in HPAT - Chile, Mexico, Netherlands, Estonia, Czech Republic
- o 13 year analysis of HPAT outcomes now in progress
- o Collaboration with Princess Maxima Centre (Utrecht) to look at outcomes of optic pathway glioma patients with GH/IGF-1 abnormalities
- o Members participating in various fora - ESPE Science Symposium on Hypothalamic Dysfunction in Childhood, International Postgraduate Course in Childhood Craniopharyngioma, Endo-ERN Webinar on Hypothalamic Obesity in Craniopharyngiomas
- o In progress - long awaited 1st UK HPAT Clinical Study Day - date finalised 13 March 2024

Plans for 2023-2024

- o Online GH tool - progressing
- o UK standards for paediatric endocrinology Jan 2019 (interim review 2024)
- o Pathway for pre-type 1 diabetes
- o Google analytics to review website engagement
- o NICE guidance on AI in children and adults due summer 2024

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2023

Diabetes

The Diabetes Clinical Services Group and the ACDC have had another active year.

Nice appraisals and Consultations

- o Diabetic Foot Problems: prevention and management (Oct 2022)
- o Hybrid Closed loop (Jan 2023)
- o Type 2 diabetes - led by T2D SIG (Feb 2023)
- o Retinopathy (Sept 2023)
- o Transition from children's to adults' services - update (Oct 2023)

Updates and Surveys-pre-Type 1 DM

- 1) News update - Teplizumab FDA announcement
 - 2) NHS England Type 1 diabetes horizon scan
 - A forward look to medicines to delay onset and progression of T1D pipeline
 - 3) Survey
 - A UK survey on the screening and management of childhood pre-clinical T1D.
- P24 Swaby et al BSPED 2023
- 4) Pre-T1D pathway under development

Representation on NHSE CYP oversight group-aim of:

Reducing health inequalities in outcomes between groups including more equitable access to treatment technology

Reducing variations in care and outcomes between paediatric diabetes departments

Improving care for those transitioning between paediatric and adult services addressing the poorer outcomes for those of transition age

Improving care for children and young adults with Type 2 diabetes

Audits

The growth hormone audit continues with the vast majority of centres contributing data. Merck Serono have agreed to fund this project with a medical educational grant.

BSPED Website Development

The BSPED website was re-developed and launched in January 2018 and continues to be maintained by BSPED committee members.

The website is aimed at:

- Providing up-to-date useful & relevant information to encourage usage of the site by health professionals as well as patients/carers
- Facilitating communication & collaboration among BSPED members
- Promoting our specialty and society nationally and internationally
- Providing a user friendly e.g. smart phone friendly version

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2023

Other supported activities

The Society supported a number of other activities in 2022--2023 which included:

- " On going support to the maintenance of the BSPED Website re-development (total cost of £10,148)
- " Funded Masters nursing courses in Paediatric Endocrinology, London Southbank University (£12,000) This takes place every 2 years and we have committed to ongoing funding for the next round in 2024-26
- " Peer-review publications, including a major paper on standards for care of CYP with adrenal insufficiency
- " Collaboration with a medical journal (Endocrinology, Diabetes and Metabolism case reports) for members to publish their research at a reduced rate
- " Travel and attendance grants for junior members presenting their research work at annual conferences to the sum of £7,000
- " Educational prizes / research awards

Sponsors

There is dedicated financial support to the Society from sponsors from the pharmaceutical industry. There are 4 tiers of support with different levels of benefits within each tier. There is also a Benefactors Hub which allows the sponsors a platform to promote educational activities. The majority of the sponsored funding is to support the Annual Meeting, growth hormone audit, research grant and educational training sessions for doctors and nurses. Some of the funding is used for Clinical Committee, Executive Committee and Clinical Special Interest Group activities. Funding also contributes to the running of the Society and Secretariat fees.

Financial review

It is the policy of the Society to maintain unrestricted funds, which are the free reserves of the charity. The reserves are held at a level that ensures the future financial viability of the Society. That level is deemed to be one that equates to a minimum of approximately one year's expenditure. Note 14 of the financial statements indicates that there are £1,011,947 unrestricted funds as at 31 August 2023. This provides sufficient funds to cover management, administration and support costs.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2023

Statement of trustees' responsibilities

The trustees are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Generally Accepted Accounting Practice.

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and which enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Small company provisions

This report has been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

This report was approved by the Board on 26 June 2024 and signed on its behalf by



Dr Fiona Regan
Treasurer

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Independent examiner's report to the trustees on the unaudited financial statements of British Society For Paediatric Endocrinology and Diabetes.

I report to the charity trustees on my examination of the financial statements of British Society For Paediatric Endocrinology and Diabetes for the year ended 31 August 2023 set out on pages 11 to 19.

Responsibilities and basis of report

As the charity trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the financial statements of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your company's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in accordance with section 386 of the Companies Act 2006; or
2. the financial statements do not accord with such records; or
3. the financial statements do not comply with relevant accounting requirements under section 396 of the Companies Act 2006 other than any requirement that the financial statements give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the financial statements have not been prepared in accordance with the Charities SORP (FRS102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Christopher Andrews ACA
Independent examiner

Leftley Rowe & Company
Chartered Accountants and Statutory Auditors
Second Floor
87 Kenton Road
Harrow
Middlesex
HA3 0AH

26 June 2024

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Statement of financial activities (incorporating the income and expenditure account)

For the year ended 31 August 2023

	Notes	Unrestricted funds £	2023 Total £	2022 Total £
Income				
Incoming resources from generating funds:				
Donations and legacies	2	187,846	187,846	193,570
Income from investments	3	4,646	4,646	122
Total income		<u>192,492</u>	<u>192,492</u>	<u>193,692</u>
Expenditure				
Costs of generating funds:				
Cost of generating voluntary income	4	6,690	6,690	6,166
Expenditure on charitable activities	5	134,358	134,358	99,952
Other	7	6,480	6,480	6,480
Total expenditure		<u>147,528</u>	<u>147,528</u>	<u>112,598</u>
Net movement in funds		44,964	44,964	81,094
Reconciliation of funds				
Total funds brought forward		966,983	966,983	885,889
Total funds carried forward		<u>1,011,947</u>	<u>1,011,947</u>	<u>966,983</u>

The statement of financial activities includes all gains and losses in the year and therefore a separate statement of total recognised gains and losses has not been prepared.

All of the above amounts relate to continuing activities.

The notes on pages 15 to 19 form an integral part of these financial statements.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Balance sheet
as at 31 August 2023

	Notes	£	2023	£	2022	£
Current assets						
Debtors	11	35,702		24,601		
Cash at bank and in hand		989,566		982,021		
		<u>1,025,268</u>		<u>1,006,622</u>		
Creditors: amounts falling due within one year	12	(13,321)		(39,639)		
Net current assets			1,011,947		966,983	
Net assets			<u>1,011,947</u>		<u>966,983</u>	
Charity Funds						
Unrestricted funds	14		1,011,947		966,983	
Total funds			<u>1,011,947</u>		<u>966,983</u>	

The Balance Sheet continues on the following page.

The notes on pages 15 to 19 form an integral part of these financial statements.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Balance sheet (continued)

Trustees statements required by the Companies Act 2006
for the year ended 31 August 2023

In approving these financial statements as trustees of the company we hereby confirm:

(a) that for the year stated above the company was entitled to the exemption conferred by section 477 of the Companies Act 2006;

(b) that no notice has been deposited at the registered office of the company pursuant to section 476 of the Companies Act 2006 requesting that an audit be conducted for the year ended 31 August 2023.

(c) that we acknowledge our responsibilities for:

(1) ensuring that the company keeps proper accounting records which comply with section 386 of the Companies Act 2006, and

(2) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its surplus or deficit for the year then ended in accordance with the requirements of sections 394 and 395, and which otherwise comply with the provisions of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

These financial statements are prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the board on 26 June 2024 and signed on its behalf by



Dr Fiona Regan
Treasurer, Trustee

Registration number 07003983

The notes on pages 15 to 19 form an integral part of these financial statements.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2023

1. Accounting policies

The principal accounting policies are summarised below. The accounting policies have been applied consistently throughout the year and the preceding year.

1.1. Basis of accounting

The financial statements have been prepared in accordance with Accounting and reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

British Society For Paediatric Endocrinology and Diabetes meets the definition of a public benefit entity under FRS 102.

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

The trustees consider that there are no material uncertainties about the Trust's ability to continue as a going concern.

The financial statements are presented in sterling which is the functional currency of the charity.

1.2. Cashflow

The charity has taken advantage of the exemption in FRS102 from the requirement to produce a cashflow statement because it is a small charity.

1.3. Incoming resources

All incoming resources are included in the statement of financial activities when the charity is entitled to the income and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income:

Voluntary income is received by way of grants, donations and gifts and is included in full in the statement of financial activities when receivable. Grants where entitlement is not conditional on the delivery of a specific performance by the charity, are recognised when the charity becomes unconditionally entitled to the grant.

Donated services and facilities are included at the value to the charity where this can be quantified. The value of services provided by volunteers has not been included.

Gifts donated for resale are included as incoming resources within activities for generating funds when they are sold.

Income from investments is included in the year in which it is receivable.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2023

1.4. Resources expended

Expenditure is recognised on an accrual basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is reported as part of the expenditure to which it relates.

Costs of generating funds comprise the costs associated with attracting voluntary income and the costs of trading for fundraising purposes including the charity's shop.

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Support costs are those costs incurred directly in support of expenditure on the objects of the charity and include project management.

2. Donations and legacies

	Unrestricted funds £	2023 Total £	2022 Total £
Benefactor income	146,500	146,500	151,500
Membership Subscriptions	41,346	41,346	42,070
	<u>187,846</u>	<u>187,846</u>	<u>193,570</u>

3. Income from investments

	Unrestricted funds £	2023 Total £	2022 Total £
Bank interest receivable	4,646	4,646	122
	<u>4,646</u>	<u>4,646</u>	<u>122</u>

4. Cost of generating voluntary income

	Unrestricted funds £	2023 Total £	2022 Total £
Commission	6,690	6,690	5,106
Credit card fees	-	-	1,060
	<u>6,690</u>	<u>6,690</u>	<u>6,166</u>

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2023

5. Expenditure on charitable activities - by fund type

	Unrestricted funds £	2023 Total £	2022 Total £
Annual meeting	87,689	87,689	-
Training	20,560	20,560	25,853
Research	26,109	26,109	74,099
	<u>134,358</u>	<u>134,358</u>	<u>99,952</u>

6. Expenditure on charitable activities - by activity

	Activities undertaken directly £	Grant funding activities £	Support costs £	2023 Total £	2022 Total £
Annual meeting	63,102	6,467	18,120	87,689	-
Training	2,440	-	18,120	20,560	25,853
Research	3,669	-	22,440	26,109	74,099
	<u>69,211</u>	<u>6,467</u>	<u>58,680</u>	<u>134,358</u>	<u>99,952</u>

7. Other

	Unrestricted funds £	2023 Total £	2022 Total £
Accountancy- monthly bookkeeping	3,960	3,960	3,960
Accountancy - yearly financial statements	2,520	2,520	2,520
	<u>6,480</u>	<u>6,480</u>	<u>6,480</u>

8. Analysis of support costs

	Annual meeting £	Training £	Research £	2023 Total £	2022 Total £
Insurance	378	378	378	1,134	1,028
General expenses	148	148	148	444	402
Secretariat fees (including website costs)	17,594	17,594	21,914	57,102	48,276
	<u>18,120</u>	<u>18,120</u>	<u>22,440</u>	<u>58,680</u>	<u>49,706</u>

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2023

9. Employees

There were no employees during the year.

No salaries or wages have been paid to the trustees during the year.

10. Taxation

The charity's activities fall within the exemptions afforded by the provisions of Part 10 Income Tax Act 2007 or Section 256 of the Taxation of Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects. Accordingly, there is no taxation charge in these accounts.

11. Debtors

	2023 £	2022 £
Other debtors	24,397	24,601
Prepayments and accrued income	11,305	-
	<u>35,702</u>	<u>24,601</u>

12. Creditors: amounts falling due within one year

	2023 £	2022 £
Trade creditors	-	26,268
Accruals and deferred income	13,321	13,371
	<u>13,321</u>	<u>39,639</u>

13. Analysis of net assets between funds

	Unrestricted funds £	Total funds £
Fund balances at 31 August 2023 as represented by:		
Current assets	1,025,268	1,025,268
Current liabilities	(13,321)	(13,321)
	<u>1,011,947</u>	<u>1,011,947</u>

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2023

14. Unrestricted funds

	Opening funds £	Incoming resources £	Outgoing resources £	At 31 August 2023 £
General reserves	<u>966,983</u>	<u>192,492</u>	<u>(147,528)</u>	<u>1,011,947</u>

Purposes of unrestricted funds

The purpose of the unrestricted funds is to advance education in paediatric endocrinology and related subjects by promoting research and disseminating the useful results of such research.

15. Restricted funds

	Opening funds £	At 31 August 2023 £
Restricted funds	<u>-</u>	<u>-</u>

16. Company limited by guarantee

British Society For Paediatric Endocrinology and Diabetes is a company limited by guarantee and accordingly does not have a share capital.

Every member of the company undertakes to contribute such amount as may be required not exceeding £1 to the assets of the charitable company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

Accounts

Charity number: 1135319
Company number: 07003983

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Trustees' annual report and financial statements

for the year ended 31 August 2022

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Contents

	Page
Legal and administrative information	1
Trustees' annual report	2 - 8
Independent examiners' report	9
Statement of financial activities	10
Balance sheet	11 - 12
Notes to the financial statements	13 - 17

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Legal and administrative information

Charity registration number 1135319

Company registration number 07003983

Business address c/o Paediatric Endocrine Department
E Floor Martin Wing
Leeds Children's Hospital
Leeds
LS1 3EX

Registered office c/o RWK Goodman LLP
69 Carter Lane
London
England
EC4V 5EQ

Trustees Dr Sabah Alvi, Treasurer
Dr Tabitha Randell, Chairman
Dr Melanie Kershaw, Secretary

Accountants Leftley Rowe & Company
Second Floor
87 Kenton Road
Harrow
Middlesex
HA3 0AH

Bankers Lloyds Bank Plc
Kings Heath
32 - 34 Alcester Road South
Kings Heath
Birmingham
B14 7PU

British Society For Paediatric Endocrinology and Diabetes

(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report) for the year ended 31 August 2022

The trustees present their report and the financial statements of the charity for the year ended 31 August 2022. The trustees have adopted the provisions of the Statement of Recommended Practice (SORP) 'Accounting and Reporting by Charities' (FRS 102) in preparing the annual report and financial statements of the charity. The directors of the charitable company are its trustees for the purposes of charity law. The directors who served during the year and up to the date of this report are set out on page 1.

Structure, governance and management

The British Society For Paediatric Endocrinology and Diabetes is constituted by a Deed of Trust and is a registered charity No 1135319. The charity changed its status to a company limited by guarantee from 01 September 2010.

Objectives and activities

The aims of the charity are to advance education in paediatric endocrinology and related subjects by promoting research and disseminating the useful results of such research.

In keeping with the aims, the Society shall have the following powers:

1. To arrange and provide for the holding of meetings, lectures and seminars.
2. To procure to be written and print, publish, issue and circulate gratuitously or otherwise such papers, periodicals, pamphlets or other documents.
3. To raise funds and to invite and receive contributions from any person or persons whatsoever by way of subscriptions and otherwise provided that the Society shall not undertake any permanent trading activities in raising funds for its primary charitable objectives.
4. To cooperate, associate or affiliate with any other charitable institutions.
5. To do all such other lawful things as are necessary for the attainment of the above objectives.

The charity has 415 elected members, who include doctors, scientists, allied professionals (specialist nurses and dieticians) and medical students. During 2021-2022, the Society has been active in presenting clinical and basic research in the field of paediatric endocrinology and diabetes, both to its own members and the wider paediatric community.

Members of the society are represented on committees with other related societies to ensure close liaison, and paediatric endocrinology representation in the drawing up of guidelines. Examples include NICE, European Endocrine Reference Network (Endo ERN), European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA), Diabetes UK, CYP Diabetes Board, Society for Endocrinology and ACDC.

The charity works closely with national agencies for paediatrics and is affiliated with the Royal College of Paediatrics and Child Health, British Endocrine Society, Royal College of Physicians and the Society for Endocrinology. The society also works closely with Patient Support Groups, such as The Child Growth Foundation, The Turner Society Support Group, British Thyroid Foundation, Pituitary Foundation and Living with CAH.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2022

Major areas of activity in support of these objectives

In 2022 we held our first in-person annual meeting since 2019, in Belfast. Being the first and due to the distance involved for many delegates, numbers of attendees were lower than pre-pandemic meetings, but it was still well attended and delivered an excellent scientific programme with a wide range of topics covering the depth and breadth of paediatric endocrinology and diabetes delivered by renowned speakers.

The BSPED 2022 Awards Session was held in which the Plenary talk by the James M Tanner Award winner was delivered by Prof Martin Savage, giving a fascinating insight into the life and works of one of the Society's luminaries.

Other highlights included:

- Expert talks/symposia delivered by expert speakers
- Parallel endocrinology and diabetes sessions
- Personal Practice sessions
- Satellite Symposia and Expert Insights sessions
- Top scoring abstracts as oral communications
- Guided poster tour
- CME day including interesting case presentations
- Nurse and Endocrine Professionals Session

Recordings have been made available to members.

BSPED Clinical Studies Group

Diabetes Clinical Studies Groups- (chaired by May Ng) priorities for 2022/23:

Identifying barriers to technology uptake-grant submitted to Diabetes UK

Mental health and psychological impact in young people-focus group work due to start Jan 2023

Establishing how to best involve children and young people in research-national CYP workshops to begin 2023

Paediatric Endocrine CSG (chaired by Indi Banerjee) priorities for 2022/23:

Focus on Rare Disease

- Engineering networks for research through SIGS
- Developing Registries
- Engage with UK RI and NIHR-focus on infrastructure, specific research PICOS
- Research active centres to complete narratives
- Develop greater trainee focus-subgroup development
- CSG representation for BSPED research grants

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2022

Royal College of Paediatrics and Child Health Annual Professional Meeting 2022

An annual fixture, the 2022 meeting was held face to face on the 30th June, in a combined session with the British Paediatric and Adolescent Bone Group.

Speakers were selected from BSPED special interest groups. There were 4 guest speakers:
Endocrine-bone management and emergencies in Duchenne Muscular Dystrophy-Dr Jarod Wong,
Clinical implications and pitfalls on the interpretation of Bone Density Scanning in children-Dr Raja Padidela,
Hypoglycaemia in Neonates and Infants-Dr Senthil Senniappan,
Type 2 Diabetes in Children and Young People-Dr Pooja Sachdev

In total 30 abstracts were submitted: there were 3 oral presentations selected for the symposium, and 27 posters presented.

Feedback for the meeting was very good.

Summary of Clinical Committee Activity 2021-22

The Clinical Committee continues to be very productive and meets regularly in remote format which enables good attendance.

Commissioning Paediatric Diabetes & Endocrinology: No change to Wales, NI & Scotland. England - NHSE Service Specification for Paediatric Endocrinology should be published shortly.

All areas are under review during 2023.

Committee membership

Welcome to

- Jarod Wong-Clinical Guidelines Officer
- Rachel Besser-Diabetes Officer
- Guftar Shaikh-Audit and Peer Review Officer

Farewell to (completed terms of office)

- May Ng-Clinical Guidelines Officer
- Fiona Campbell-Diabetes Officer
- Indi Banerjee-Audit and Peer Review Officer

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2022

Achievements 1: ENDOCRINOLOGY

- Paediatric Adrenal Insufficiency Guidance
- Online GH audit tool
- GH pros and cons leaflet

BSPED endorsed standards

- Paediatric Endocrine Conditions and Suggested Types and Frequency of Clinical Reviews during and after the COVID-19 crises

Guideline updates

- Hormone Supplementation for Pubertal Induction in Girls
- BSPED position on RCPCH resource 'Seeking and providing external second opinions

Special Interest Groups

DSD	Zainaba Mohamed	2016- 2025
T2DM	BillyWhite/PoojaSachdev	2019-2023
HPAT	Paul Dimitri	2019- 2023
Thyroid	Catherine Peters/TimCheetham	2020- 2024
Growth Disorders	Helen Storr	2020-2024
CAH	Nils Krone	2021-2024

Achievements a: SIG Thyroid

- Exploring the presentation of secondary hypothyroidism as part of discussions regarding the feasibility and likely benefits of implementing a screening programme for this condition in the UK.
- Exploring the potential strategies for obtaining regional outcome data following the diagnosis of primary CHT-preliminary meeting held with many of the laboratory and clinical leads from regional screening laboratories

Achievements b: SIG DSD

- BSPED DSD SIG terms of reference formalised-Jan 2022
 - Virtual meetings (47 members)
 - UK prenatal dexamethasone consensus-reference (revised document in March 2022).
- Appointed new chair Dr Zainaba Mohammed

Achievements c: SIG CAH

- Initiation of national service evaluation with clinician and patient/ dailyfeedback(ongoing).
- OngoingI-CAH study on Real world data collection of CAH care provision.
- Advice to genomics England 100,000 NGS programme, sub-group providing further advice on CAH and adrenal genes
- Subgroup on clinical standards will meet to discuss development

Achievements d: SIG HPAT

- Monthly national HPAT MDT to discuss complex hypothalamic and pituitary tumour cases-attendance from European colleagues
- Attend the European Craniopharyngioma MDT for complex cases
- Invited lecture from SIG members at ESPE Science Symposium on Hypothalamic Dysfunction in Childhood / 3 publications
- Planned national meeting on hypothalamo-pituitary dysfunction

British Society For Paediatric Endocrinology and Diabetes **(A company limited by guarantee)**

Report of the trustees' (incorporating the directors' report) **for the year ended 31 August 2022**

Achievements e: SIG T2DM

- Contributed to and reviewed the resources for the newDigiBeteT2 platform
- The new T2 diabetes guideline was published at the start of 2022 thanks to input from the working group and ACDC/BSPED.
- Two new subgroups:
- HCP training-online study day planned and develop a training package
- Improving Outcomes-exploring implementation of the ACDC/BSPEDManagement of T2 diabetes in CYP guidelines and barriers to meeting these as indicated in the NPDA T2 Spotlight Audit.
- Interfaces with the CEW clinics

Plans for 2022-2023

- Paediatric Adrenal Insufficiency: publication / website / materials
- Launch online GH tool
- Embed new clinical committee members
- Review SIG

Achievements: 2 DIABETES

- DKA Guideline/Integrated Care Pathway/DKA Fluids Calculator. New and improved BSPED Paediatric DKA Calculator in 2022
- Type 2 guideline prepared by BSPED Type 2 SIG (National Network Type 2Subgroup)/ACDC
- Endorsed NICE Guidance
- Vaccinations
- Partnership Working

Conclusions-diabetes

There have been key initiatives over the last 12 years which seem to have contributed to significantly improving CYP diabetes outcomes in England and Wales (NPDA, NCYPDN and Regional Networks, Best Practice Tariff, RCPCH QA and QI Programme). The key to positive change seems to have been in a consolidation of effort (rather than any one initiative) under the shared umbrella of NCYPDN and RCPCH continuing to work with MDTs on reviewing and updating targets and methods of achieving them. There is great potential in continuing this trend via further consolidation with oversight and reinforcement of the existing infrastructure from NHSE/I.

While formulated differently, the Delivery Plan Aims are perfectly linked with the NHS ECYA Diabetes strategic priorities-sometimes overlapping, sometimes complementing them (for example, workforce, while not a priority in itself, it is nonetheless instrumental in making the priorities happen). The Aim Groups will provide a useful mechanism to support thedelivery of national priorities through its direct reach to the clinical and patient communities-being able to feed back from the ground up and take things from strategic NHSE level back to clinical settings for testing and adaptation (a learning loop). The Aim Groups/subgroups are perfectly placed to support the development of the CYA Diabetes Right Care tool-kit.

Peer Review

Bart's, Belfast, Birmingham, Evelina, Oxford, Manchester and St George have all undergone the virtual peer review process. Indi Banerjee has now completed his term of office and has been replaced by Dr Guftar Shaikh, but will provide some support in order to ease the handover of this process to the new Officer.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2022

Audits

The growth hormone audit continues with the vast majority of centres contributing data. Merck Serono have agreed to fund this project with a medical educational grant.

BSPED Website Development

The BSPED website was re-developed and launched in January 2018 and continues to be maintained by BSPED committee members.

The website is aimed at:

- Providing up-to-date useful & relevant information to encourage usage of the site by health professionals as well as patients/carers
 - Facilitating communication & collaboration among BSPED members
 - Promoting our specialty and society nationally and internationally
 - Providing a user friendly e.g. smart phone friendly version
-

Other supported activities

The Society supported a number of other activities in 2021-2022 which included:

- Ongoing support to the maintenance of the BSPED Website re-development (total cost of £6,701)
- Funded Masters nursing courses in Paediatric Endocrinology, London Southbank University (£35,000). This takes place every 2 years and we have committed to ongoing funding for the next round in 2022-24.
- Peer-review publications
- Collaboration with a medical journal (Endocrinology, Diabetes and Metabolism case reports) for members to publish their research at a reduced rate
- Travel grants for junior members presenting their research work at annual conferences to the sum of £6,000
- Educational prizes/awards were resumed this year and the BSPED funded research grants of £36,000

Benefactors

There is a dedicated financial support to the Society from benefactors from the pharmaceutical industry. There are 4 tiers of support with different levels of benefits within each tier. The majority of the Benefactor funding is to support the Annual Meeting, growth hormone audit, research grant and educational training sessions for doctors and nurses. Some of the funding is used for Clinical Committee, Executive Committee and Clinical Special Interest Group activities. Funding also contributes to the running of the Society and Secretariat fees.

Financial review

It is the policy of the Society to maintain unrestricted funds, which are the free reserves of the charity. The reserves are held at a level that ensures the future financial viability of the Society. That level is deemed to be one that equates to a minimum of approximately one year's expenditure. Note 14 of the financial statements indicates that there are £966,983 unrestricted funds as at 31 August 2022. This provides sufficient funds to cover management, administration and support costs.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2022

Statement of trustees' responsibilities

The trustees are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Generally Accepted Accounting Practice.

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and which enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Small company provisions

This report has been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

This report was approved by the Board on 22 May 2023 and signed on its behalf by



Dr Sabah Alvi, MBChB, MD, FRCPCH
Consultant in Paediatric and Adolescent Endocrinology
Honorary Senior Lecturer, University of Leeds
Treasurer of the British Society for Paediatric Endocrinology and Diabetes

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Independent examiner's report to the trustees on the unaudited financial statements of British Society For Paediatric Endocrinology and Diabetes.

I report to the charity trustees on my examination of the financial statements of British Society For Paediatric Endocrinology and Diabetes for the year ended 31 August 2022 set out on pages 11 to 17.

Responsibilities and basis of report

As the charity trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the financial statements of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your company's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in accordance with section 386 of the Companies Act 2006; or
2. the financial statements do not accord with such records; or
3. the financial statements do not comply with relevant accounting requirements under section 396 of the Companies Act 2006 other than any requirement that the financial statements give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the financial statements have not been prepared in accordance with the Charities SORP (FRS102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Christopher Andrews ACA
Independent examiner

Leftley Rowe & Company
Chartered Accountants and Statutory Auditors
Second Floor
87 Kenton Road
Harrow
Middlesex
HA3 0AH

22 May 2023

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Statement of financial activities (incorporating the income and expenditure account)

For the year ended 31 August 2022

	Notes	Unrestricted funds £	2022 Total £	2021 Total £
Income				
Incoming resources from generating funds:				
Donations and legacies	2	193,570	193,570	116,228
Income from investments	3	122	122	88
Total income		<u>193,692</u>	<u>193,692</u>	<u>116,316</u>
Expenditure				
Costs of generating funds:				
Cost of generating voluntary income	4	6,166	6,166	3,591
Expenditure on charitable activities	5	99,952	99,952	68,806
Other	7	6,480	6,480	6,480
Total expenditure		<u>112,598</u>	<u>112,598</u>	<u>78,877</u>
Net movement in funds		81,094	81,094	37,439
Reconciliation of funds				
Total funds brought forward		885,889	885,889	848,450
Total funds carried forward		<u>966,983</u>	<u>966,983</u>	<u>885,889</u>

The statement of financial activities includes all gains and losses in the year and therefore a separate statement of total recognised gains and losses has not been prepared.

All of the above amounts relate to continuing activities.

The notes on pages 13 to 17 form an integral part of these financial statements.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Balance sheet
as at 31 August 2022

	Notes	£	2022	£	£	2021	£
Current assets							
Debtors	11	24,601			37,350		
Cash at bank and in hand		982,021			896,030		
		<u>1,006,622</u>			<u>933,380</u>		
Creditors: amounts falling due within one year	12	<u>(39,639)</u>			<u>(47,491)</u>		
Net current assets				966,983			885,889
Net assets				<u>966,983</u>			<u>885,889</u>
Charity Funds	13						
Unrestricted funds				966,983			885,889
Total funds				<u>966,983</u>			<u>885,889</u>

The Balance Sheet continues on the following page.

The notes on pages 13 to 17 form an integral part of these financial statements.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Balance sheet (continued)

Trustees statements required by the Companies Act 2006
for the year ended 31 August 2022

In approving these financial statements as trustees of the company we hereby confirm:

(a) that for the year stated above the company was entitled to the exemption conferred by section 477 of the Companies Act 2006;

(b) that no notice has been deposited at the registered office of the company pursuant to section 476 of the Companies Act 2006 requesting that an audit be conducted for the year ended 31 August 2022.

(c) that we acknowledge our responsibilities for:

(1) ensuring that the company keeps proper accounting records which comply with section 386 of the Companies Act 2006, and

(2) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its surplus or deficit for the year then ended in accordance with the requirements of sections 394 and 395, and which otherwise comply with the provisions of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

These financial statements are prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the board on 22 May 2023 and signed on its behalf by



Dr Sabah Alvi, MBChB, MD, FRCPCH
Consultant in Paediatric and Adolescent Endocrinology
Honorary Senior Lecturer, University of Leeds
Treasurer of the British Society for Paediatric Endocrinology and Diabetes

Registration number 07003983

The notes on pages 13 to 17 form an integral part of these financial statements.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2022

1. Accounting policies

The principal accounting policies are summarised below. The accounting policies have been applied consistently throughout the year and the preceding year.

1.1. Basis of accounting

The financial statements have been prepared in accordance with Accounting and reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

British Society For Paediatric Endocrinology and Diabetes meets the definition of a public benefit entity under FRS 102.

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

The trustees consider that there are no material uncertainties about the Trust's ability to continue as a going concern.

The financial statements are presented in sterling which is the functional currency of the charity.

1.2. Cashflow

The charity has taken advantage of the exemption in FRS102 from the requirement to produce a cashflow statement because it is a small charity.

1.3. Incoming resources

All incoming resources are included in the statement of financial activities when the charity is entitled to the income and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income:

Voluntary income is received by way of grants, donations and gifts and is included in full in the statement of financial activities when receivable. Grants where entitlement is not conditional on the delivery of a specific performance by the charity, are recognised when the charity becomes unconditionally entitled to the grant.

Donated services and facilities are included at the value to the charity where this can be quantified. The value of services provided by volunteers has not been included.

Gifts donated for resale are included as incoming resources within activities for generating funds when they are sold.

Income from investments is included in the year in which it is receivable.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2022

1.4. Resources expended

Expenditure is recognised on an accrual basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is reported as part of the expenditure to which it relates.

Costs of generating funds comprise the costs associated with attracting voluntary income and the costs of trading for fundraising purposes including the charity's shop.

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Support costs are those costs incurred directly in support of expenditure on the objects of the charity and include project management.

2. Donations and legacies

	Unrestricted funds £	2022 Total £	2021 Total £
Benefactor income	151,500	151,500	72,000
Membership Subscriptions	42,070	42,070	44,228
	<u>193,570</u>	<u>193,570</u>	<u>116,228</u>

3. Income from investments

	Unrestricted funds £	2022 Total £	2021 Total £
Bank interest receivable	122	122	88
	<u>122</u>	<u>122</u>	<u>88</u>

4. Cost of generating voluntary income

	Unrestricted funds £	2022 Total £	2021 Total £
Commission	5,106	5,106	2,460
Credit card fees	1,060	1,060	1,131
	<u>6,166</u>	<u>6,166</u>	<u>3,591</u>

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2022

5. Expenditure on charitable activities - by fund type

	Unrestricted funds £	2022 Total £	2021 Total £
Training	25,853	25,853	32,319
Research	74,099	74,099	36,487
	<u>99,952</u>	<u>99,952</u>	<u>68,806</u>

6. Expenditure on charitable activities - by activity

	Activities undertaken directly £	Support costs £	2022 Total £	2021 Total £
Training	1,000	24,853	25,853	32,319
Research	49,246	24,853	74,099	36,487
	<u>50,246</u>	<u>49,706</u>	<u>99,952</u>	<u>68,806</u>

7. Other

	Unrestricted funds £	2022 Total £	2021 Total £
Accountancy- monthly bookkeeping	3,960	3,960	3,960
Accountancy - yearly financial statements	2,520	2,520	2,520
	<u>6,480</u>	<u>6,480</u>	<u>6,480</u>

8. Analysis of support costs

	Training £	Research £	2022 Total £	2021 Total £
Insurance	514	514	1,028	944
General expenses	201	201	402	688
Secretariat fees (including website costs)	24,138	24,138	48,276	47,344
	<u>24,853</u>	<u>24,853</u>	<u>49,706</u>	<u>48,976</u>

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2022

9. Employees

There were no employees during the year.

No salaries or wages have been paid to the trustees during the year.

10. Taxation

The charity's activities fall within the exemptions afforded by the provisions of Part 10 Income Tax Act 2007 or Section 256 of the Taxation of Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects. Accordingly, there is no taxation charge in these accounts.

11. Debtors

	2022 £	2021 £
Other debtors	24,601	22,350
Prepayments and accrued income	-	15,000
	<u>24,601</u>	<u>37,350</u>

12. Creditors: amounts falling due within one year

	2022 £	2021 £
Trade creditors	26,268	945
Accruals and deferred income	13,371	46,546
	<u>39,639</u>	<u>47,491</u>

13. Analysis of net assets between funds

	Unrestricted funds £	Total funds £
Fund balances at 31 August 2022 as represented by:		
Current assets	1,006,622	1,006,622
Current liabilities	(39,639)	(39,639)
	<u>966,983</u>	<u>966,983</u>

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2022

14. Unrestricted funds	Opening funds £	Incoming resources £	Outgoing resources £	At 31 August 2022 £
General reserves	<u>885,889</u>	<u>193,692</u>	<u>(112,598)</u>	<u>966,983</u>

Purposes of unrestricted funds

The purpose of the unrestricted funds is to advance education in paediatric endocrinology and related subjects by promoting research and disseminating the useful results of such research.

15. Restricted funds	Opening funds £	At 31 August 2022 £
Restricted funds	<u>-</u>	<u>-</u>

16. Company limited by guarantee

British Society For Paediatric Endocrinology and Diabetes is a company limited by guarantee and accordingly does not have a share capital.

Every member of the company undertakes to contribute such amount as may be required not exceeding £1 to the assets of the charitable company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

Accounts

Charity number: 1135319
Company number: 07003983

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)
Trustees' annual report and financial statements
for the year ended 31 August 2021

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Contents

	Page
Legal and administrative information	1
Trustees' annual report	2 - 6
Independent examiners' report	7
Statement of financial activities	8
Balance sheet	9 - 10
Notes to the financial statements	11 - 16

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Legal and administrative information

Charity registration number 1135319

Company registration number 07003983

Business address c/o Paediatric Endocrine Department
A Floor Brotherton Wing
Leeds Children's Hospital
Leeds
LS1 3EX

Registered office 69 Carter Lane
London
England
EC4V 5EQ

Trustees Dr Sabah Alvi, Treasurer
Dr Tabitha Randell, Chairman
Dr Melanie Kershaw, Secretary

Accountants Leftley Rowe & Company
Second Floor
87 Kenton Road
Harrow
Middlesex
HA3 0AH

Bankers Lloyds Bank Plc
Kings Heath
32 - 34 Alcester Road South
Kings Heath
Birmingham
B14 7PU

HSBC Plc
1 Centenary Square
Birmingham
B1 1HQ

British Society For Paediatric Endocrinology and Diabetes **(A company limited by guarantee)**

Report of the trustees' (incorporating the directors' report) **for the year ended 31 August 2021**

The trustees present their report and the financial statements of the charity for the year ended 31 August 2021. The trustees have adopted the provisions of the Statement of Recommended Practice (SORP) 'Accounting and Reporting by Charities' (FRS 102) in preparing the annual report and financial statements of the charity. The directors of the charitable company are its trustees for the purposes of charity law. The directors who served during the year and up to the date of this report are set out on page 1.

Structure, governance and management

The British Society For Paediatric Endocrinology and Diabetes is constituted by a Deed of Trust and is a registered charity No 1135319. The charity changed its status to a company limited by guarantee from 01 September 2010.

Objectives and activities

The aims of the charity are to advance education in paediatric endocrinology and related subjects by promoting research and disseminating the useful results of such research.

In keeping with the aims, the Society shall have the following powers:

1. To arrange and provide for the holding of meetings, lectures and seminars.
2. To procure to be written and print, publish, issue and circulate gratuitously or otherwise such papers, periodicals, pamphlets or other documents.
3. To raise funds and to invite and receive contributions from any person or persons whatsoever by way of subscriptions and otherwise provided that the Society shall not undertake any permanent trading activities in raising funds for its primary charitable objectives.
4. To cooperate, associate or affiliate with any other charitable institutions.
5. To do all such other lawful things as are necessary for the attainment of the above objectives.

The charity has 411 elected members, who include doctors, scientists, allied professionals (specialist nurses and dietitians) and medical students. During 2020-2021, the Society has been active in presenting clinical and basic research in the field of paediatric endocrinology and diabetes, both to its own members and the wider paediatric community.

Members of the society are represented on committees with other related societies to ensure close liaison, and paediatric endocrinology representation in the drawing up of guidelines. Examples include NICE, European Endocrine Reference Network (Endo ERN), European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA), Diabetes UK, CYP Diabetes Board, Society for Endocrinology and ACDC.

The charity works closely with national agencies for paediatrics and is affiliated with the Royal College of Paediatrics and Child Health, British Endocrine Society, Royal College of Physicians and the Society for Endocrinology. The society also works closely with Patient Support Groups, such as The Child Growth Foundation, The Turner Society Support Group, British Thyroid Foundation, Pituitary Foundation and Living with CAH.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2021

Major areas of activity in support of these objectives

Due to the Covid -19 pandemic, the Society made the decision to cancel the annual professional meeting, but an annual general meeting for members went ahead virtually.

Other activities however, continued apace, and possibly even more productively due to the ease of remote working and virtual meetings. We had changes of personnel (all voluntary and professional members of the Society) Exec Chair - Tabitha Randell, Exec Secretary - Melanie Kershaw Endocrine Nurse Officer - Isabel Sharratt CME Officer / RCPCH Academic Liaison Officer - Dinesh Giri CSAC Trainee Representative - Katherine Hawton (Grid) CSAC Trainee Representative - Abi Fernando (Spin) Information Officer - Angela Lucas-Herald

We saw the launch of the Virtual Paediatric Endocrine Group (VPEG) which meets quarterly to discuss challenging cases and acts as a multiprofessional sounding board which effectively gives a patient in one centre or District General Hospital the benefit of multiple opinions-not just a second opinion!

BSPED Clinical Studies Group

During 2020-21 meetings were held in virtual format and discussions focused on the impact of Covid-19 on research as a whole and the role of CSG to sustain research through the pandemic. The Centre Research Narrative is to showcase UK research in paediatric endocrinology, encourage centres to develop research expertise, and to foster collaborative networks. There have been challenges to develop new research, obtain grants and deliver existing research, but a robust research strategy has been established and the group is finalising the Research Priorities Document, now with NIHR, along with topic discussions on national perspectives, rare diseases, clinical research facilities and the Trainee perspective.

Royal College of Paediatrics and Child Health Annual Professional Meeting 2021

The meeting was held on the 17th June in Virtual format with a BSPED special interest group symposium.

It was as part of a combined session with British Society of Paediatric Dermatology and British Paediatric and Adolescent Bone Group.

There were 5 guest speakers and 2 abstract presentations (Precocious puberty - Prof Butler, Unexplained fractures - Prof Mughal, Nutritional rickets - Dr. Julies, Acne and Adolescence - Dr. Wood, Hidden endocrine disorders: what the skin can tell you - Dr. Hulse).

35 abstracts were submitted, of which 2 were accepted for oral presentation at the symposium, 1 was accepted to the plenary in main meeting, 31 were presented as posters, with 1 abstract being rejected.

Feedback for the meeting was very good.

Summary of Clinical Committee Activity 2020-21.

The Clinical Committee has been remarkably productive despite/because of lockdown.

The main areas of focus for the committee have been:

Continued development of special interest groups (SIGs): The BSPED executive team and clinical committee have agreed to support up to 6 SIGs, chaired by BSPED members. In general, each SIG will be supported for up to 3 years, with the main purpose of the group to complete a finite work programme.

In 2020-21 we have the following SIGs: CAH -Type 2 diabetes (CYP T2D) - Hypothalamic & Pituitary Axis Tumour (HPAT) - Disorders of Sexual Development (DSD) -Growth Disorders - Thyroid

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2021

Achievements over the last year have been:

BSPED online communication strategy: website, twitter, facebook

Establishment of Special Interest Group for Congenital Adrenal Hyperplasia

Virtual peer reviews

Guideline development

BSPED UK Consensus National Guidelines for Sex Hormone Priming for Growth Hormone (GH) Stimulation Testing

Guideline updates

Shared Care Guidelines: Use of Gonadotrophin Releasing Hormone (GnRH) Agonists - Triptorelin

Endorsement of

UK DMD Standards of Care and patient leaflets for Bone, Puberty & Adrenal Insufficiency

GnRH Analogue Stimulation Testing to Investigate Precocious Puberty

The Neonatal and Paediatric Pharmacist Group (NPPG) position statement regarding the use of steroid medication warning cards

Child growth foundation: Silver Russell Syndrome booklet

Contributed to

UK Guidance on the Initial Evaluation of an Infant or an Adolescent with a Suspected Disorder of Sex Development

CLCG: Craniopharyngioma - guideline consultation

Continuous glucose monitoring for patients with recurrent hypoglycaemia (non-diabetes)

DKA guideline

BSPED Guideline for the Management of Children and Young People under the age of 18 years with Diabetic Ketoacidosis - 2021

Type 2 guideline

A practical approach to the management of Type 2 diabetes in children and young people under 18 years

Endorsed NICE Guidance:

Diabetes (type 1 and type 2) in children and young people: diagnosis and management

Vaccination

BSPED statement on Covid-19 vaccination in children aged 12 - 15 with underlying health conditions

Peer Review

Bart's, Belfast, Birmingham, Evelina, Oxford, Manchester and St George have all undergone the virtual peer review process. Indi Banerjee will stay on as Audit and Peer Review Officer longer in order to ease the handover of this process to the new Officer.

Audits: The growth hormone audit continues with the vast majority of centres contributing data. Merck Serono have agreed to fund this project with a medical educational grant.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2021

BSPED Website Development

The BSPED website was re-developed and launched in January 2018 and continues to be maintained by BSPED committee members.

The website is aimed at:

- Providing up-to-date useful & relevant information to encourage usage of the site by health professionals as well as patients/carers
- Facilitating communication & collaboration among BSPED members
- Promoting our specialty and society nationally and internationally
- Providing a user friendly e.g. smart phone friendly version

Other supported activities

The Society supported a number of other activities in 2020-2021 which included:

- Ongoing support to the maintenance of the BSPED Website re-development (total cost of £8,855)
- Funded Masters nursing courses in Paediatric Endocrinology, London Southbank University (£7,110). This takes place every 2 years and we have committed to ongoing funding for the next round in 2022-24.
- Peer-review publications
- Collaboration with a medical journal (Endocrinology, Diabetes and Metabolism case reports) for members to publish their research at a reduced rate
- Travel grants for junior members presenting their research work at annual conferences have not been granted this year as there was no physical meeting, but these will be resumed when the conference is live
- There were no educational prizes or awards granted this year, but BSPED supported an African Paediatric Research Fellow with a grant of £12,000 as in previous years, to enhance learning opportunities where there may otherwise be poor resources and limited training.

Benefactors

There is a dedicated financial support to the Society from benefactors from the pharmaceutical industry. There are 4 tiers of support with different levels of benefits within each tier. The majority of the Benefactor funding is to support the Annual Meeting, growth hormone audit, research grant and educational training sessions for doctors and nurses. Some of the funding is used for Clinical Committee, Executive Committee and Clinical Special Interest Group activities. Funding also contributes to the running of the Society and Secretariat fees.

Financial review

It is the policy of the Society to maintain unrestricted funds, which are the free reserves of the charity. The reserves are held at a level that ensures the future financial viability of the Society. That level is deemed to be one that equates to a minimum of approximately one year's expenditure. Note 15 of the financial statements indicates that there are £885,889 unrestricted funds as at 31 August 2021. This provides sufficient funds to cover management, administration and support costs.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2021

Funds held as custodian trustee on behalf of others

In recent years the Society has received monies from Novo Nordisk which are to be paid to the University of Cambridge to support a research project (NESGAS) using growth hormone in children born small for gestational age (SGA). Novo Nordisk have paid the money through the Society to the University of Cambridge in order to avoid large fees which the University would otherwise have charged. Thus the Society effectively acts as a Custodian Trustee. The Society has no control of the money and therefore these funds are not treated as income or expenditure in the financial statements.

No such amounts were received by the Society during either the current or comparative year. Payments of £nil (2020: £50,000) were made to the University of Cambridge. At the balance sheet date an amount of £nil (2020: £nil) was being held by the Society in this capacity as Custodian Trustee.

Statement of trustees' responsibilities

The trustees are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Generally Accepted Accounting Practice.

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and which enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Small company provisions

This report has been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

This report was approved by the Board on 23 June 2022 and signed on its behalf by



Dr Sabah Alvi, MBChB, MD, FRCPCH
Consultant in Paediatric Endocrinology and Gender Dysphoria
Treasurer of the British Society of Paediatric Endocrinology and Diabetes

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Independent examiner's report to the trustees on the unaudited financial statements of British Society For Paediatric Endocrinology and Diabetes.

I report to the charity trustees on my examination of the financial statements of British Society For Paediatric Endocrinology and Diabetes for the year ended 31 August 2021 set out on pages 8 to 16.

Responsibilities and basis of report

As the charity trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the financial statements of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your company's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in accordance with section 386 of the Companies Act 2006; or
2. the financial statements do not accord with such records; or
3. the financial statements do not comply with relevant accounting requirements under section 396 of the Companies Act 2006 other than any requirement that the financial statements give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the financial statements have not been prepared in accordance with the Charities SORP (FRS102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Christopher Andrews ACA
Independent examiner

Leftley Rowe and Company
Chartered Accountants and Statutory Auditors
Second Floor
87 Kenton Road
Harrow
Middlesex
HA3 0AH

23 June 2022

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Statement of financial activities (incorporating the income and expenditure account)

For the year ended 31 August 2021

	Notes	Unrestricted funds £	2021 Total £	2020 Total £
Income				
Incoming resources from generating funds:				
Donations and legacies	2	116,228	116,228	52,916
Income from investments	3	88	88	499
Income from charitable activities	4	-	-	154,617
Total income		<u>116,316</u>	<u>116,316</u>	<u>208,032</u>
Expenditure				
Costs of generating funds:				
Cost of generating voluntary income	5	2,460	2,460	1,350
Expenditure on charitable activities	6	69,937	69,937	229,040
Other	8	6,480	6,480	6,480
Total expenditure		<u>78,877</u>	<u>78,877</u>	<u>236,870</u>
Net movement in funds		37,439	37,439	(28,838)
Reconciliation of funds				
Total funds brought forward		848,450	848,450	877,288
Total funds carried forward		<u>885,889</u>	<u>885,889</u>	<u>848,450</u>

The statement of financial activities includes all gains and losses in the year and therefore a separate statement of total recognised gains and losses has not been prepared.

All of the above amounts relate to continuing activities.

The notes on pages 11 to 16 form an integral part of these financial statements.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Balance sheet
as at 31 August 2021

	Notes	£	2021 £	£	2020 £
Current assets					
Debtors	12	37,350		19,239	
Cash at bank and in hand		896,030		867,284	
		<u>933,380</u>		<u>886,523</u>	
Creditors: amounts falling due within one year	13	(47,491)		(38,073)	
Net current assets			<u>885,889</u>		<u>848,450</u>
Net assets			<u>885,889</u>		<u>848,450</u>
Charity Funds	14				
Unrestricted funds			<u>885,889</u>		<u>848,450</u>
Total funds			<u>885,889</u>		<u>848,450</u>

The Balance Sheet continues on the following page.

The notes on pages 11 to 16 form an integral part of these financial statements.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Balance sheet (continued)

Trustees statements required by the Companies Act 2006
for the year ended 31 August 2021

In approving these financial statements as trustees of the company we hereby confirm:

(a) that for the year stated above the company was entitled to the exemption conferred by section 477 of the Companies Act 2006 ;

(b) that no notice has been deposited at the registered office of the company pursuant to section 476 of the Companies Act 2006 requesting that an audit be conducted for the year ended 31 August 2021.

(c) that we acknowledge our responsibilities for:

(1) ensuring that the company keeps proper accounting records which comply with section 386 of the Companies Act 2006, and

(2) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its surplus or deficit for the year then ended in accordance with the requirements of sections 394 and 395, and which otherwise comply with the provisions of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

These financial statements are prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies .

The financial statements were approved by the board on 23 June 2022 and signed on its behalf by



Dr Sabah Alvi, MBChB, MD, FRCPCH
Consultant in Paediatric Endocrinology and Gender Dysphoria
Treasurer of the British Society of Paediatric Endocrinology and Diabetes

Registration number 07003983

The notes on pages 11 to 16 form an integral part of these financial statements.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2021

1. Accounting policies

The principal accounting policies are summarised below. The accounting policies have been applied consistently throughout the year and the preceding year.

1.1. Basis of accounting

The financial statements have been prepared in accordance with Accounting and reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

British Society For Paediatric Endocrinology and Diabetes meets the definition of a public benefit entity under FRS 102.

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

The trustees consider that there are no material uncertainties about the Trust's ability to continue as a going concern.

The financial statements are presented in sterling which is the functional currency of the charity.

1.2. Cashflow

The charity has taken advantage of the exemption in FRS102 from the requirement to produce a cashflow statement because it is a small charity.

1.3. Incoming resources

All incoming resources are included in the statement of financial activities when the charity is entitled to the income and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income:

Voluntary income is received by way of grants, donations and gifts and is included in full in the statement of financial activities when receivable. Grants where entitlement is not conditional on the delivery of a specific performance by the charity, are recognised when the charity becomes unconditionally entitled to the grant.

Donated services and facilities are included at the value to the charity where this can be quantified. The value of services provided by volunteers has not been included.

Gifts donated for resale are included as incoming resources within activities for generating funds when they are sold.

Income from investments is included in the year in which it is receivable.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2021

1.4. Resources expended

Expenditure is recognised on an accrual basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is reported as part of the expenditure to which it relates.

Costs of generating funds comprise the costs associated with attracting voluntary income and the costs of trading for fundraising purposes including the charity's shop.

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Support costs are those costs incurred directly in support of expenditure on the objects of the charity and include project management.

2. Donations and legacies

	Unrestricted funds £	2021 Total £	2020 Total £
Benefactor income	72,000	72,000	-
Donations	-	-	530
Membership Subscriptions	44,228	44,228	52,386
	<u>116,228</u>	<u>116,228</u>	<u>52,916</u>

The Society recently altered the timing of invoices raised to benefactors in order to align with the financial year end of the Society. Consequently no benefactor income was received in the year ended 31 August 2020.

3. Income from investments

	Unrestricted funds £	2021 Total £	2020 Total £
Bank interest receivable	88	88	499
	<u>88</u>	<u>88</u>	<u>499</u>

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2021

4. Income from charitable activities

	2021	2020
	Total	Total
	£	£
Income from annual meeting	-	154,617
	<u>-</u>	<u>154,617</u>
	<u>-</u>	<u>154,617</u>

Due to the Covid-19 pandemic, the Society made the decision not to hold the annual professional meeting during the 2021 financial year.

5. Cost of generating voluntary income

	Unrestricted	2021	2020
	funds	Total	Total
	£	£	£
Commission	2,460	2,460	1,350
	<u>2,460</u>	<u>2,460</u>	<u>1,350</u>
	<u>2,460</u>	<u>2,460</u>	<u>1,350</u>

6. Expenditure on charitable activities - by fund type

	Unrestricted	2021	2020
	funds	Total	Total
	£	£	£
Annual meeting	-	-	172,127
Training	32,884	32,884	18,582
Research	37,053	37,053	38,331
	<u>69,937</u>	<u>69,937</u>	<u>229,040</u>
	<u>69,937</u>	<u>69,937</u>	<u>229,040</u>

7. Expenditure on charitable activities - by activity

	Activities		2021	2020
	undertaken	Support	Total	Total
	directly	costs	£	£
	£	£		
Annual meeting	-	-	-	172,127
Training	7,830	25,054	32,884	18,582
Research	12,000	25,053	37,053	38,331
	<u>19,830</u>	<u>50,107</u>	<u>69,937</u>	<u>229,040</u>
	<u>19,830</u>	<u>50,107</u>	<u>69,937</u>	<u>229,040</u>

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2021

8. Other

	Unrestricted funds £	2021 Total £	2020 Total £
Accountancy- monthly bookkeeping	3,960	3,960	3,960
Accountancy - yearly financial statements	2,520	2,520	2,520
	<u>6,480</u>	<u>6,480</u>	<u>6,480</u>

9. Analysis of support costs

	Training £	Research £	2021 Total £	2020 Total £
Insurance	472	472	944	1,230
Travel expenses	910	909	1,819	1,432
Secretariat fees (including website costs)	23,672	23,672	47,344	46,248
	<u>25,054</u>	<u>25,053</u>	<u>50,107</u>	<u>48,910</u>

10. Employees

There were no employees during the year.

No salaries or wages have been paid to the trustees during the year.

11. Taxation

The charity's activities fall within the exemptions afforded by the provisions of Part 10 Income Tax Act 2007 or Section 256 of the Taxation of Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects. Accordingly, there is no taxation charge in these accounts.

12. Debtors

	2021 £	2020 £
Other debtors	22,350	14,239
Prepayments and accrued income	15,000	5,000
	<u>37,350</u>	<u>19,239</u>

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2021

13. Creditors: amounts falling due within one year

	2021	2020
	£	£
Trade creditors	945	-
Accruals and deferred income	46,546	38,073
	<u>47,491</u>	<u>38,073</u>

14. Analysis of net assets between funds

	Unrestricted funds	Total funds
	£	£
Fund balances at 31 August 2021 as represented by:		
Current assets	933,380	933,380
Current liabilities	(47,491)	(47,491)
	<u>885,889</u>	<u>885,889</u>

15. Unrestricted funds

	Opening funds	Incoming resources	Outgoing resources	At 31 August 2021
	£	£	£	£
General reserves	<u>848,450</u>	<u>116,316</u>	<u>(78,877)</u>	<u>885,889</u>

Purposes of unrestricted funds

The purpose of the unrestricted funds is to advance education in paediatric endocrinology and related subjects by promoting research and disseminating the useful results of such research.

16. Restricted funds

	Opening funds	At 31 August 2021
	£	£
Restricted funds	<u>-</u>	<u>-</u>

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2021

17. Company limited by guarantee

British Society For Paediatric Endocrinology and Diabetes is a company limited by guarantee and accordingly does not have a share capital.

Every member of the company undertakes to contribute such amount as may be required not exceeding £1 to the assets of the charitable company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

18. Custodian Trustee

In recent years the Society has received monies from Novo Nordisk which are to be paid to the University of Cambridge to support a research project (NESGAS) using growth hormone in children born small for gestational age (SGA). Novo Nordisk have paid the money through the Society to the University of Cambridge in order to avoid large fees which the University would otherwise have charged. Thus the Society effectively acts as a Custodian Trustee. The Society has no control of the money and therefore these funds are not treated as income or expenditure in the financial statements.

No such amounts were received by the Society during either the current or comparative year. Payments of £nil (2020: £50,000) were made to the University of Cambridge. At the balance sheet date an amount of £nil (2020: £nil) was being held by the Society in this capacity as Custodian Trustee.

Accounts

Charity number: 1135319
Company number: 07003983

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Trustees' annual report and financial statements
for the year ended 31 August 2020

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Contents

	Page
Legal and administrative information	1
Trustees' annual report	2 - 7
Independent examiners' report	8
Statement of financial activities	9
Balance sheet	10 - 11
Notes to the financial statements	12 - 17

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Legal and administrative information

Charity registration number 1135319

Company registration number 07003983

Business address c/o Paediatric Endocrine Department
A Floor Brotherton Wing
Leeds Children's Hospital
Leeds
LS1 3EX

Registered office 69 Carter Lane
London
England
EC4V 5EQ

Trustees Dr Sabah Alvi, Treasurer
Dr Justin Davies, Chairman (resigned 12 November 2020)
Dr Jo Blair, Secretary (resigned 12 November 2020)
Dr Melanie Joy Roshina Kershaw (appointed 12 November 2020)
Dr Tabitha Randell (appointed 12 November 2020)

Accountants Leftley Rowe and Company
Second Floor
87 Kenton Road
Harrow
Middlesex
HA3 0AH

Bankers Lloyds Bank Plc
Kings Heath
32 - 34 Alcester Road South
Kings Heath
Birmingham
B14 7PU

HSBC Plc
1 Centenary Square
Birmingham
B1 1HQ

British Society For Paediatric Endocrinology and Diabetes

(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report) for the year ended 31 August 2020

The trustees present their report and the financial statements of the charity for the year ended 31 August 2020. The trustees have adopted the provisions of the Statement of Recommended Practice (SORP) 'Accounting and Reporting by Charities' (FRS 102) in preparing the annual report and financial statements of the charity. The directors of the charitable company are its trustees for the purposes of charity law. The directors who served during the year and up to the date of this report are set out on page 1.

Structure, governance and management

The British Society For Paediatric Endocrinology and Diabetes is constituted by a Deed of Trust and is a registered charity No 1135319. The charity changed its status to a company limited by guarantee from 01 September 2010.

Objectives and activities

The aims of the charity are to advance education in paediatric endocrinology and related subjects by promoting research and disseminating the useful results of such research.

In keeping with the aims, the Society shall have the following powers:

1. To arrange and provide for the holding of meetings, lectures and seminars.
2. To procure to be written and print, publish, issue and circulate gratuitously or otherwise such papers, periodicals, pamphlets or other documents.
3. To raise funds and to invite and receive contributions from any person or persons whatsoever by way of subscriptions and otherwise provided that the Society shall not undertake any permanent trading activities in raising funds for its primary charitable objectives.
4. To cooperate, associate or affiliate with any other charitable institutions.
5. To do all such other lawful things as are necessary for the attainment of the above objectives.

The charity has 450 elected members, who include doctors, scientists, allied professionals (specialist nurses and dieticians) and medical students. During 2019-2020, the Society has been active in presenting clinical and basic research in the field of paediatric endocrinology and diabetes, both to its own members and the wider paediatric community.

Members of the society are represented on committees with other related societies to ensure close liaison, and paediatric endocrinology representation in the drawing up of guidelines. Examples include NICE, European Endocrine Reference Network (Endo ERN), European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA), Diabetes UK, CYP Diabetes Board, Society for Endocrinology and ACDC.

The charity works closely with national agencies for paediatrics and is affiliated with the Royal College of Paediatrics and Child Health, British Endocrine Society, Royal College of Physicians and the Society for Endocrinology. The society also works closely with Patient Support Groups, such as The Child Growth Foundation, The Turner Society Support Group, British Thyroid Foundation, Pituitary Foundation and Living with CAH.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2020

Major areas of activity in support of these objectives

Main meeting: Cardiff 2019

The 47th Annual Meeting of the Society was held in November 2019 at City Hall, Cardiff. The meeting was attended by 420 delegates from throughout the UK and Ireland and attracted 130 abstracts, presented in oral and poster form.

The Continuing Medical Education programme on day 1 (182 delegates) provided a varied focus on key clinical and training matters in paediatric endocrinology and diabetes. Topics covered included investigation, evaluation and education of children with differences of sex development, trends and treatment of CAH and assessment of pituitary tumours, hypopituitarism and quality improvement methods and optimal self- management of Type 1 diabetes.

The main conference day for endocrine professionals covered topics on long term outcomes of PCOS, childhood brain tumours and maternal thyroid function in pregnancy and childhood. There was a dedicated symposium on thyroid conditions, covering surgery, management of thyrotoxicosis and congenital TSH deficiency. There were two symposia, one on digital technology in endocrinology and the other with the keynote speaker, Professor Wass giving an enlightening talk on the history of paediatric endocrinology.

The main diabetes themes covered nutrition, food science and cooking and using carbohydrates and calories in everyday diabetes practice. Speakers also looked at the challenges of caring for diabetic children in socially deprived and ethnic minority groups, and how to avoid hypoglycaemia during sporting activity. The increase in adolescent Type 2 diabetes was reviewed and the use of social media in enhancing delivery of care and education was a prominent theme.

As usual there was a dedicated poster session with oral presentations and poster tours.

The meeting received excellent feedback from the participants.

RCPCH BSPED Meeting, October 2020

Due to the Covid-19 pandemic, the spring meeting of the RCPCH (usually held in May), was postponed to October and held virtually. The BSPED special interest group symposium was organised by the CME Officer and held on 1st October 2020. This was provided as a live online free conference on the Zoom platform. One thousand and eighty-three delegates registered, with 545 "attending" on the day. The content was made available to registrants on demand through the RCPCH compass until December 2020; 7% (n=178) of the registrants were international, from the Middle East, India, Burma, Iraq, Pakistan, Hong Kong, Greece, Egypt and the USA.

Twenty-seven abstracts were submitted, and 3 Guest Speakers spoke on delayed puberty, adolescent gynaecology, and the challenges of engaging young adults with diabetes. There were 6 abstract presentations.

Feedback was extremely positive, appreciating support for continuous learning in difficult times, with live interaction, and lively debate, although there was the inevitable lag in questions reaching chairs through the online medium. Overall the quality of presentation and the audio-visuals was appreciated and the convenience of avoiding travel enhanced participation.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2020

BSPED Clinical Studies Group

It was previously decided that the two groups (endocrine and diabetes) would meet separately in the future, with separate chairs. Members had been encouraged to apply for the chairs of the groups but unfortunately one of the chairs remained vacant. The 2019-20 activities were therefore still carried out under a single umbrella with the lead of the endocrine CSG Professor Banerjee presenting the report-members overlapped between the 2 groups and new members had been approved. It was recognised that a redesign of the CSG was essential over 2019-20 but there had been several challenges due to leadership changes, Covid19 uncertainty, and the need to re-energize. There had been re-engagement with the Endocrine CSG, and support from Amy Mulligan from the NIHR had been obtained. A virtual meeting was held via Google Hangout, and new Parent Support Groups associated with the Pituitary Foundation and Child Growth Foundation were established.

The CSG had also focused strongly on research and had updated Terms of Reference of the CSG Strategy. A draft will be circulated with regular work in progress dashboard to report programmes of work. Rare endocrine disease research prioritisation, NIHR CRN and subspecialty updates will be provided and the group will also engage with external research relevant to BSPED, identify stakeholders, seek support for research infrastructure and identify further directions for research.

Diabetes Activities

There is a very strong diabetes care and research programme within the Society. Both Dr Fiona Campbell, the current Diabetes Officer and Dr May Ng, Chair of the Diabetes Research Group in Young people, and Chair of the Association of Children's Diabetes Clinicians, presented updates on recent and ongoing longer term projects demonstrating increased improvement in clinical management with better clinical results and use of technology to promote good practice and engage young people.

Summary of Clinical Committee Activity 2019-20.

Tabitha Randell was replaced by Talat Mushtaq as Chair of the Clinical Committee and took over in May 2020. He has been shadowing Dr Randell since May 2019. The Committee also welcomed new members Pooja Sachdev as Clinical Standards Officer and Jennifer Calvert as Diabetes AHP/Nurses Officer.

The main areas of focus for the committee have been:

Diabetes: BSPED Interim Guideline for the Management of CYP under the age of 18 years with DKA - the DKA Integrated Care Pathway was endorsed. In collaboration with ACDC, the following guidelines were endorsed: Care of the Well Child Newly Diagnosed with Type 1 Diabetes; Management of Hypoglycaemia in Children and Young People with Type 1 Diabetes; A Practical Approach to the Self-Management of Diabetes As An Inpatient for CYP Under 18 years; A Practical Approach to the Management of Continuous Glucose Monitoring (CGM) / Real-Time Flash Glucose Scanning (FGS) in Type 1 Diabetes Mellitus in CYP Under 18 years; A Practical Approach to the Management of Steroid, Chemotherapy or Transplant-Induced Hyperglycaemia or Diabetes in CYP Under 18 years in the Acute or Inpatient Setting. The Committee also consulted on NICE guidelines on Diabetes in Pregnancy, and Diabetes (type 1 and type 2) in Children and Young people: Diagnosis and Management.

Endocrinology: Development of the BSPED Adrenal Insufficiency card; Endorsement of UK DMD Standards of Care and patient leaflets for Bone, Puberty Insufficiency. Also contributed to the UK DSD Guidance Revision 2020, CCLG guidelines on Childhood Craniopharyngioma, and Guidance and Pathways for the Assessment of Children with Breast Symptoms. The BSPED UK Consensus National Guidelines for Sex Hormone Priming are nearing completion, and the GH Audit has now been closed.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2020

Development of special interest groups (SIGs): The BSPED executive team and clinical committee have agreed to support up to 6 SIGs, chaired by BSPED members. In general, each SIG will be supported for up to 3 years, with the main purpose of the group to complete a finite work programme. The DKA SIG has been looking at the evidence for the management of DKA, following the revised BSPED guidelines being published a few years ago. The DKA calculator has now been fully revised but remains offline while legal liability is being explored, but the SIG has now been closed having achieved the desired aim. However, a new SIG for Type 2 Diabetes has been established aiming to focus on audit and obesity. The SIG for Congenital Hyperinsulinism initiated late 2018 is developing a network care model along with NHSE and mapping tertiary centres and GSHs. The involvement of neonatologists to identify and treat hypoglycaemia is a crucial aim. The DSD SIG was established four years ago and this will continue longer term; it now has 44 members and a new Chair, and is currently updating information on prenatal dexamethasone treatment. It has also updated the UK DSD guidance paper 2020, and endorsed 2 Facebook support groups. It is currently contributing to an NHSE stakeholder exercise in the provision of elective surgical care in babies and children with DSD. New for 2020 are a Growth disorders and a thyroid disorders SIG. Finally HPAT has merged with the craniopharyngioma SIOP to work on pituitary tumours and develop guidelines on management of craniopharyngioma.

All SIG will be reviewed to ensure they continue to meet the Terms of Reference (available at: <https://www.bsped.org.uk/media/1586/bsped-sigs-tor-feb-2019-final.pdf>)

Peer review: The peer review process has been revised and the first centre in the new cycle of peer reviews was Nottingham, carried out in July 2019. The plan is to peer review 3-4 centres/year over the next 5 years, with centres covering the costs of the reviewers and BSPED coordinating the process. The clinical committee has also made a brief video explaining how the process of peer review works and the expectations for peer reviewers and centres alike. However, due to the pandemic this year the programme was changed to develop virtual peer review and guidance on how this would proceed has been produced.

The clinical committee will continue to hold four meetings a year; in common with most societies, all these meetings have been held on virtual platforms from the beginning of the Covid 19 pandemic in March 2020.

BSPED Website Development

The BSPED website was re-developed and launched in January 2018 and continues to be maintained by BSPED committee members.

The website is aimed at:

- Providing up-to-date useful & relevant information to encourage usage of the site by health professionals as well as patients/carers
- Facilitating communication & collaboration among BSPED members
- Promoting our specialty and society nationally and internationally
- Providing a user friendly e.g. smart phone friendly version

Other supported activities

The Society supported a number of other activities in 2019-2020 which included:

- Ongoing support to the maintenance of the BSPED Website re-development (total cost of £8,597)
- A post for a Growth Hormone audit co-ordinator (£11,808).
- Peer-review publications
- Collaboration with a medical journal (Endocrinology, Diabetes and Metabolism case reports) for members to publish their research at a reduced rate
- BSPED-supported research prizes (£10 000)
- Three prizes (£50 each) awarded for best CME presentation, abstract and poster at the annual conference.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2020

Benefactors

There is a dedicated financial support to the Society from benefactors from the pharmaceutical industry. There are 4 tiers of support with different levels of benefits within each tier. The majority of the Benefactor funding is to support the Annual Meeting, growth hormone audit, research grant and educational training sessions for doctors and nurses. Some of funding is used for Clinical Committee, Executive Committee and Clinical Study Group activities. Funding also contributes to the running of the Society and Secretariat fees.

Financial review

It is the policy of the Society to maintain unrestricted funds, which are the free reserves of the charity. The reserves are held at a level that ensures the future financial viability of the Society. That level is deemed to be one that equates to a minimum of approximately one year's expenditure. Note 16 of the financial statements indicates that there are £848,450 unrestricted funds as at 31 August 2020. This provides sufficient funds to cover management, administration and support costs.

Funds held as custodian trustee on behalf of others

In recent years the Society has received monies from Novo Nordisk which are to be paid to the University of Cambridge to support a research project (NESGAS) using growth hormone in children born small for gestational age (SGA). Novo Nordisk have paid the money through the Society to the University of Cambridge in order to avoid large fees which the University would otherwise have charged. Thus the Society effectively acts as a Custodian Trustee. The Society has no control of the money and therefore these funds are not treated as income or expenditure in the financial statements.

During the year the Society received £nil (2019: £20,000) from Novo Nordisk and made payments of £50,000 (2019: £nil) to the University of Cambridge. At the balance sheet date an amount of £nil (2019: £50,000) was being held by the Society in this capacity as Custodian Trustee.

Statement of trustees' responsibilities

The trustees are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Generally Accepted Accounting Practice.

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Report of the trustees' (incorporating the directors' report)
for the year ended 31 August 2020

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and which enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Small company provisions

This report has been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

This report was approved by the Board on 25 May 2021 and signed on its behalf by



Dr Sabah Alvi, MBChB, MD, FRCPCH
Consultant in Paediatric Endocrinology and Gender Dysphoria
Treasurer of the British Society of Paediatric Endocrinology and Diabetes

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Independent examiner's report to the trustees on the unaudited financial statements of British Society For Paediatric Endocrinology and Diabetes.

I report to the charity trustees on my examination of the financial statements of British Society For Paediatric Endocrinology and Diabetes for the year ended 31 August 2020 set out on pages 9 to 17.

Responsibilities and basis of report

As the charity trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the financial statements of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your company's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in accordance with section 386 of the Companies Act 2006; or
2. the financial statements do not accord with such records; or
3. the financial statements do not comply with relevant accounting requirements under section 396 of the Companies Act 2006 other than any requirement that the financial statements give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the financial statements have not been prepared in accordance with the Charities SORP (FRS102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Christopher Andrews ACA
Independent examiner

Leftley Rowe and Company
Chartered Accountants and Statutory Auditors
Second Floor
87 Kenton Road
Harrow
Middlesex
HA3 0AH

25 May 2021

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Statement of financial activities (incorporating the income and expenditure account)

For the year ended 31 August 2020

	Notes	Unrestricted funds £	2020 Total £	2019 Total £
Income				
Incoming resources from generating funds:				
Donations and legacies	2	52,916	52,916	147,138
Income from investments	3	499	499	499
Income from charitable activities	4	154,617	154,617	154,037
Other incoming resources	5	-	-	69
Total income		<u>208,032</u>	<u>208,032</u>	<u>301,743</u>
Expenditure				
Costs of generating funds:				
Cost of generating voluntary income	6	1,350	1,350	-
Expenditure on charitable activities	7	229,040	229,040	227,254
Other	9	6,480	6,480	5,220
Total expenditure		<u>236,870</u>	<u>236,870</u>	<u>232,474</u>
Net movement in funds		(28,838)	(28,838)	69,269
Reconciliation of funds				
Total funds brought forward		877,288	877,288	808,019
Total funds carried forward		<u>848,450</u>	<u>848,450</u>	<u>877,288</u>

The statement of financial activities includes all gains and losses in the year and therefore a separate statement of total recognised gains and losses has not been prepared.

All of the above amounts relate to continuing activities.

The notes on pages 12 to 17 form an integral part of these financial statements.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Balance sheet
as at 31 August 2020

		2020		2019	
	Notes	£	£	£	£
Current assets					
Debtors	13	19,239		117,061	
Cash at bank and in hand		867,284		823,560	
		<u>886,523</u>		<u>940,621</u>	
Creditors: amounts falling due within one year	14	<u>(38,073)</u>		<u>(63,333)</u>	
Net current assets			<u>848,450</u>		<u>877,288</u>
Net assets			<u>848,450</u>		<u>877,288</u>
Charity Funds	15				
Unrestricted funds			<u>848,450</u>		<u>877,288</u>
Total funds			<u>848,450</u>		<u>877,288</u>

The Balance Sheet continues on the following page.

The notes on pages 12 to 17 form an integral part of these financial statements.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Balance sheet (continued)

Trustees statements required by the Companies Act 2006
for the year ended 31 August 2020

In approving these financial statements as trustees of the company we hereby confirm:

(a) that for the year stated above the company was entitled to the exemption conferred by section 477 of the Companies Act 2006 ;

(b) that no notice has been deposited at the registered office of the company pursuant to section 476 of the Companies Act 2006 requesting that an audit be conducted for the year ended 31 August 2020.

(c) that we acknowledge our responsibilities for:

(1) ensuring that the company keeps proper accounting records which comply with section 386 of the Companies Act 2006, and

(2) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its surplus or deficit for the year then ended in accordance with the requirements of sections 394 and 395, and which otherwise comply with the provisions of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

These financial statements are prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies .

The financial statements were approved by the board on 25 May 2021 and signed on its behalf by



Dr Sabah Alvi, MBChB, MD, FRCPCH
Consultant in Paediatric Endocrinology and Gender Dysphoria
Treasurer of the British Society of Paediatric Endocrinology and Diabetes

Registration number 07003983

The notes on pages 12 to 17 form an integral part of these financial statements.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2020

1. Accounting policies

The principal accounting policies are summarised below. The accounting policies have been applied consistently throughout the year and the preceding year.

1.1. Basis of accounting

The financial statements have been prepared in accordance with Accounting and reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

British Society For Paediatric Endocrinology and Diabetes meets the definition of a public benefit entity under FRS 102.

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

The trustees consider that there are no material uncertainties about the Trust's ability to continue as a going concern.

The financial statements are presented in sterling which is the functional currency of the charity.

1.2. Cashflow

The charity has taken advantage of the exemption in FRS102 from the requirement to produce a cashflow statement because it is a small charity.

1.3. Incoming resources

All incoming resources are included in the statement of financial activities when the charity is entitled to the income and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income:

Voluntary income is received by way of grants, donations and gifts and is included in full in the statement of financial activities when receivable. Grants where entitlement is not conditional on the delivery of a specific performance by the charity, are recognised when the charity becomes unconditionally entitled to the grant.

Donated services and facilities are included at the value to the charity where this can be quantified. The value of services provided by volunteers has not been included.

Gifts donated for resale are included as incoming resources within activities for generating funds when they are sold.

Income from investments is included in the year in which it is receivable.

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2020

1.4. Resources expended

Expenditure is recognised on an accrual basis as a liability is incurred. Expenditure includes any VAT which cannot be fully recovered, and is reported as part of the expenditure to which it relates.

Costs of generating funds comprise the costs associated with attracting voluntary income and the costs of trading for fundraising purposes including the charity's shop.

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Support costs are those costs incurred directly in support of expenditure on the objects of the charity and include project management.

2. Donations and legacies

	Unrestricted funds £	2020 Total £	2019 Total £
Benefactor income	-	-	108,000
Donations	530	530	-
Membership Subscriptions	52,386	52,386	39,138
	<u>52,916</u>	<u>52,916</u>	<u>147,138</u>

The Society has altered the timing of invoices raised to benefactors in order to align with the financial year end of the Society. Consequently no benefactor income was received in the year ended 31 August 2020. Subsequent to 31 August 2020 benefactor income has been received in the year ended 31 August 2021.

3. Income from investments

	Unrestricted funds £	2020 Total £	2019 Total £
Bank interest receivable	499	499	499
	<u>499</u>	<u>499</u>	<u>499</u>

4. Income from charitable activities

	Unrestricted funds £	2020 Total £	2019 Total £
Income from annual meeting	154,617	154,617	154,037
	<u>154,617</u>	<u>154,617</u>	<u>154,037</u>

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2020

5. Other incoming resources

	2020	2019
	Total	Total
	£	£
Other income	-	69
	<u>-</u>	<u>69</u>
	<u>-</u>	<u>69</u>

6. Cost of generating voluntary income

	Unrestricted	2020	2019
	funds	Total	Total
	£	£	£
Commission	1,350	1,350	-
	<u>1,350</u>	<u>1,350</u>	<u>-</u>
	<u>1,350</u>	<u>1,350</u>	<u>-</u>

7. Expenditure on charitable activities - by fund type

	Unrestricted	2020	2019
	funds	Total	Total
	£	£	£
Annual meeting	172,127	172,127	172,097
Training	18,582	18,582	19,501
Research	38,331	38,331	35,656
	<u>229,040</u>	<u>229,040</u>	<u>227,254</u>
	<u>229,040</u>	<u>229,040</u>	<u>227,254</u>

8. Expenditure on charitable activities - by activity

	Activities	Grant	Support	2020	2019
	undertaken	funding	costs	Total	Total
	directly	activities	£	£	£
	£	£	£	£	£
Annual meeting	151,930	3,842	16,355	172,127	172,097
Training	2,304	-	16,278	18,582	19,501
Research	22,054	-	16,277	38,331	35,656
	<u>176,288</u>	<u>3,842</u>	<u>48,910</u>	<u>229,040</u>	<u>227,254</u>
	<u>176,288</u>	<u>3,842</u>	<u>48,910</u>	<u>229,040</u>	<u>227,254</u>

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2020

9. Other

	Unrestricted funds £	2020 Total £	2019 Total £
Accountancy- monthly bookkeeping	3,960	3,960	3,960
Accountancy - yearly financial statements	2,520	2,520	2,520
Timing difference	-	-	(1,260)
	<u>6,480</u>	<u>6,480</u>	<u>5,220</u>

10. Analysis of support costs

	Annual meeting £	Training £	Research £	2020 Total £	2019 Total £
Insurance	410	410	410	1,230	882
Travel expenses	529	452	451	1,432	3,873
Secretariat fees (including website costs)	15,416	15,416	15,416	46,248	48,588
	<u>16,355</u>	<u>16,278</u>	<u>16,277</u>	<u>48,910</u>	<u>53,343</u>

11. Employees

There were no employees during the year.

No salaries or wages have been paid to the trustees during the year.

12. Taxation

The charity's activities fall within the exemptions afforded by the provisions of Part 10 Income Tax Act 2007 or Section 256 of the Taxation of Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects. Accordingly, there is no taxation charge in these accounts.

13. Debtors

	2020 £	2019 £
Other debtors	14,239	19,061
Prepayments and accrued income	5,000	98,000
	<u>19,239</u>	<u>117,061</u>

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2020

14. Creditors: amounts falling due within one year

	2020	2019
	£	£
Other creditors	-	50,105
Accruals and deferred income	38,073	13,228
	<u>38,073</u>	<u>63,333</u>

15. Analysis of net assets between funds

	Unrestricted funds	Total funds
	£	£
Fund balances at 31 August 2020 as represented by:		
Current assets	886,523	886,523
Current liabilities	(38,073)	(38,073)
	<u>848,450</u>	<u>848,450</u>

16. Unrestricted funds

	Opening funds	Incoming resources	Outgoing resources	At 31 August 2020
	£	£	£	£
General reserves	<u>877,288</u>	<u>208,032</u>	<u>(236,870)</u>	<u>848,450</u>

Purposes of unrestricted funds

The purpose of the unrestricted funds is to advance education in paediatric endocrinology and related subjects by promoting research and disseminating the useful results of such research.

17. Restricted funds

	Opening funds	At 31 August 2020
	£	£
Restricted funds	<u>-</u>	<u>-</u>

British Society For Paediatric Endocrinology and Diabetes
(A company limited by guarantee)

Notes to financial statements
for the year ended 31 August 2020

18. Company limited by guarantee

British Society For Paediatric Endocrinology and Diabetes is a company limited by guarantee and accordingly does not have a share capital.

Every member of the company undertakes to contribute such amount as may be required not exceeding £1 to the assets of the charitable company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

19. Custodian Trustee

In recent years the Society has received monies from Novo Nordisk which are to be paid to the University of Cambridge to support a research project (NESGAS) using growth hormone in children born small for gestational age (SGA). Novo Nordisk have paid the money through the Society to the University of Cambridge in order to avoid large fees which the University would otherwise have charged. Thus the Society effectively acts as a Custodian Trustee. The Society has no control of the money and therefore these funds are not treated as income or expenditure in the financial statements.

During the year the Society received £nil (2019: £20,000) from Novo Nordisk and made payments of £50,000 (2019: £nil) to the University of Cambridge. At the balance sheet date an amount of £nil (2019: £50,000) was being held by the Society in this capacity as Custodian Trustee.